Details of the Drug

General Information of Drug (ID: DMVXFYE)

• Drug Name: Vinorelbine
• Synonyms: Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01CA04: Vinorelbine
  L01CA: Vinca alkaloids and analogues
  L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 778.9
  Logarithm of the Partition Coefficient (xlogp); 3.6
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 11
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 20 mL/min/kg [4]
  Elimination: Urinary excretion of unchanged drug accounts for less than 20% of an intravenous dose, with fecal elimination accounting for an additional 30% to 60% [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 27.7 - 43.6 hours [6]
  Metabolism: The drug is metabolized via the hepatic [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.87% [4]
  Vd: The volume of distribution (Vd) of drug is 25.4-40.1 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 1000 mg/mL [3]
• Chemical Identifiers:
  Formula: C45H54N4O8
  IUPAC Name: methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
  Canonical SMILES: CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
  InChI: InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1
  InChIKey: GBABOYUKABKIAF-IELIFDKJSA-N
• Cross-matching ID:
  PubChem CID: 5311497
  ChEBI ID: CHEBI:480999
  CAS Number: 71486-22-1
  UNII: Q6C979R91Y
  DrugBank ID: DB00361
  TTD ID: D01HTL
  VARIDT ID: DR01343
  INTEDE ID: DR1696
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Gene/Protein Processing	[12]
Epithelial cell adhesion molecule (EPCAM)	OTHBZK5X	EPCAM_HUMAN	Gene/Protein Processing	[13]
Equilibrative nucleoside transporter 1 (SLC29A1)	OTLOOZZS	S29A1_HUMAN	Drug Response	[14]
Keratin, type I cytoskeletal 18 (KRT18)	OTVLQFIP	K1C18_HUMAN	Gene/Protein Processing	[15]
Nucleophosmin (NPM1)	OTTBYYT0	NPM_HUMAN	Drug Response	[16]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Gene/Protein Processing	[12]
Splicing factor 45 (RBM17)	OT9ROJCL	SPF45_HUMAN	Drug Response	[17]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Gene/Protein Processing	[18]
Vitamin K-dependent protein C (PROC)	OTGVH484	PROC_HUMAN	Gene/Protein Processing	[19]

Molecular Expression Atlas of This Drug

• The Studied Disease: Advanced cancer
• ICD Disease Classification: 2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tubulin (TUB)	DTT	NO-GeName	4.29E-15	0.3	0.59
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.61E-73	-1.15E+00	-1.66E+00
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	6.51E-02	-2.38E-02	-9.58E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.87E-03	-6.67E-02	-2.12E-01

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1; GDSC2	-5.08	-2.3615	-5.5675	20.3114
ES8	GDSC1; GDSC2	-8.8355	-7.4426	-8.8357	55.3244
EW-12	GDSC2	-8.5047	-5.1799	-8.6001	51.865
EW-1	GDSC1; GDSC2	-8.1687	-6.4297	-8.1722	48.6434
MHH-ES-1	GDSC1; GDSC2	-7.9881	-6.5679	-7.9891	46.8288
ES7	GDSC1; GDSC2	-7.8272	-5.0494	-7.8969	45.3972
EW-16	GDSC1; GDSC2	-7.7705	-6.4192	-7.7714	44.6452
ES1	GDSC1; GDSC2	-7.6874	-5.2542	-7.7296	43.9514
EW-18	GDSC1; GDSC2	-7.4511	-4.7506	-7.5337	41.7515
NY	GDSC1; GDSC2	-7.4378	-6.0566	-7.4396	41.3119
HuO9	GDSC1; GDSC2	-7.3086	-2.3551	-7.9705	42.0286
A-673	GDSC1; GDSC2	-7.0377	-6.2898	-7.0377	37.2879
EW-13	GDSC1	-7.0238	-4.4493	-7.1846	39.0501
SK-ES-1	GDSC1; GDSC2	-6.9915	-4.1684	-7.1314	37.4498
EW-22	GDSC2	-6.8603	-3.8026	-7.0636	36.4284
MG-63	GDSC1; GDSC2	-6.5834	-0.8234	-7.7765	37.427
HOS	GDSC1; GDSC2	-6.5	-5.5016	-6.5008	31.896
HuO-3N1	GDSC1; GDSC2	-6.3818	-0.911	-7.5289	35.6051
SK-PN-DW	GDSC1; GDSC2	-6.3136	-3.6233	-6.5098	31.0044
SJSA-1	GDSC1; GDSC2	-5.8602	-3.6805	-6.003	26.2087
EW-7	GDSC1; GDSC2	-5.8419	-2.8733	-6.2065	27.186
CHSA0108	GDSC1; GDSC2	-5.5659	-2.1652	-6.1613	25.686
TC-71	GDSC1; GDSC2	-5.3458	-3.9024	-5.4035	20.6057
CHSA8926	GDSC1; GDSC2	-5.1107	4.8782	-8.9939	34.4861
EW-11	GDSC1; GDSC2	-4.9761	-0.6553	-6.199	23.3883
NOS-1 [Human HNSCC]	GDSC1; GDSC2	-4.0984	0.4944	-5.9104	18.5381
EW-3	GDSC1; GDSC2	-3.838	-0.097	-5.3824	14.5619
CHSA0011	GDSC1; GDSC2	-3.3745	0.8236	-5.4387	13.4488
U2OS	GDSC1; GDSC2	-3.1479	2.8203	-6.2492	17.3898
CADO-ES1	GDSC2	-3.1163	-0.1709	-4.7295	8.3253
CAL-78	GDSC1; GDSC2	-3.0794	3.8009	-6.6833	19.4035
EW-24	GDSC1; GDSC2	-2.8927	1.6487	-5.4593	12.1998
ES6	GDSC1; GDSC2	-2.1014	7.6074	-7.8057	21.6388
U-CH2	GDSC2	-1.569	3.8134	-5.5556	9.5799
SaOS-2	GDSC1; GDSC2	-1.3181	6.7631	-6.8077	15.4833
CAL-72	GDSC1; GDSC2	-1.1807	8.4456	-7.5307	18.3409
ES4	GDSC1; GDSC2	-0.3747	17.5003	-11.3905	27.9415
ES5	GDSC1; GDSC2	-0.2977	10.6452	-7.974	18.1845
H-EMC-SS	GDSC1; GDSC2	-0.1346	5.6664	-5.5198	6.7498
G-292 clone A141B1	GDSC1; GDSC2	0.0113	6.6872	-5.8969	8.4023

Cancer Drug Sensitivity Data Curated from 167 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JM1	GDSC1; GDSC2	-6.5726	-4.8688	-6.5957	32.7358
NB4	GDSC1; GDSC2	-9.8005	-8.7224	-9.8005	65.0089
SUP-B8	GDSC2	-9.3944	-7.8332	-9.3947	60.9094
CRO-AP2	GDSC2	-9.1203	-5.3723	-9.2306	57.3227
Karpas-231	GDSC1; GDSC2	-9.0346	-7.4237	-9.0352	57.3077
ATN-1	GDSC1; GDSC2	-8.9517	-7.7576	-8.9517	56.4933
ALL-SIL	GDSC1; GDSC2	-8.827	-6.3303	-8.8448	55.1105
BONNA-12	GDSC2	-8.8112	-6.4994	-8.8226	54.9936
GA-10	GDSC1; GDSC2	-8.7963	-7.3523	-8.7966	54.93
JeKo-1	GDSC2	-8.7563	-6.5047	-8.7665	54.4629
SU-DHL-5	GDSC1; GDSC2	-8.7439	-7.5628	-8.7439	54.4089
SR	GDSC1; GDSC2	-8.7427	-4.6181	-8.941	53.8153
SIG-M5	GDSC1; GDSC2	-8.7379	-7.7144	-8.7379	54.3495
CTV-1	GDSC1; GDSC2	-8.7364	-5.4938	-8.8098	54.0448
A4/Fukuda	GDSC1; GDSC2	-8.7335	-6.2162	-8.7537	54.1937
OCI-Ly19	GDSC1; GDSC2	-8.6952	-6.494	-8.7045	53.8659
SU-DHL-6	GDSC1; GDSC2	-8.6935	-6.814	-8.6967	53.8801
BL-41	GDSC1; GDSC2	-8.6732	-7.5479	-8.6732	53.7
DEL	GDSC1; GDSC2	-8.6268	-6.3648	-8.6387	53.1836
697	GDSC1; GDSC2	-8.6079	-7.3713	-8.608	53.0447
ALL-PO	GDSC1; GDSC2	-8.5937	-6.8612	-8.5957	52.8923
SU-DHL-10	GDSC1; GDSC2	-8.5364	-7.3192	-8.5364	52.3267
SU-DHL-16	GDSC1; GDSC2	-8.5028	-7.0838	-8.5032	51.9883
OCI-Ly7	GDSC2	-8.4701	-7.2054	-8.4703	51.6622
SKM-1	GDSC2	-8.4535	-5.8882	-8.4819	51.4542
P32/ISH	GDSC1; GDSC2	-8.4343	-6.9861	-8.4349	51.302
Farage	GDSC1; GDSC2	-8.4321	-6.6353	-8.4352	51.2752
Karpas-620	GDSC1; GDSC2	-8.4241	-5.2759	-8.5033	51.1286
ST486	GDSC1; GDSC2	-8.353	-6.5979	-8.3559	50.4854
NKM-1	GDSC1; GDSC2	-8.2776	-6.5052	-8.281	49.7316
RCH-ACV	GDSC2	-8.1984	-6.3355	-8.2038	48.9419
QIMR-WIL	GDSC1; GDSC2	-8.1913	-6.1311	-8.2017	48.8759
ML-2	GDSC1; GDSC2	-8.1535	-6.5794	-8.1552	48.4886
EoL-1	GDSC1; GDSC2	-8.1377	-7.0999	-8.1378	48.3271
NU-DUL-1	GDSC1; GDSC2	-8.0854	-6.4295	-8.0881	47.8083
SUP-M2	GDSC1; GDSC2	-8.0523	-5.9114	-8.0674	47.5008
MOLM-16	GDSC2	-8.0426	-5.1929	-8.109	47.4835
HC-1	GDSC1; GDSC2	-8.0123	-6.6104	-8.0131	47.071
Ramos.2G6.4C10	GDSC1; GDSC2	-7.8855	-6.6777	-7.8858	45.7971
MHH-PREB-1	GDSC1; GDSC2	-7.8748	-6.663	-7.875	45.6892
JJN-3	GDSC1; GDSC2	-7.8325	-6.2195	-7.8356	45.275
JSC-1	GDSC1; GDSC2	-7.8216	-4.9945	-7.8973	45.3566
KE-37	GDSC1; GDSC2	-7.8202	-6.4473	-7.8211	45.1444
NALM-6	GDSC1; GDSC2	-7.8114	-6.6453	-7.8116	45.0532
MOLT-13	GDSC2	-7.8027	-6.6361	-7.8029	44.9662
MOLT-4	GDSC1; GDSC2	-7.7769	-6.2791	-7.7789	44.714
Hs 445	GDSC1; GDSC2	-7.7675	-5.645	-7.7867	44.6771
BALL-1	GDSC1; GDSC2	-7.7416	-6.6662	-7.7418	44.3529
CCRF-CEM	GDSC1; GDSC2	-7.674	-6.3512	-7.6749	43.6776
SUP-T1	GDSC1; GDSC2	-7.6735	-3.8935	-7.928	44.3442
DoHH2	GDSC1; GDSC2	-7.6347	-5.5748	-7.6534	43.3508
RPMI-6666	GDSC1; GDSC2	-7.6347	-5.6293	-7.6507	43.3412
Karpas-45	GDSC1; GDSC2	-7.6074	-4.5439	-7.7307	43.4013
OPM-2	GDSC1; GDSC2	-7.5923	-5.8615	-7.5992	42.8823
CML-T1	GDSC2	-7.5798	-3.699	-7.8714	43.5647
MOLM-13	GDSC1; GDSC2	-7.5766	-4.9677	-7.6409	42.9263
Jurkat	GDSC2	-7.5589	-4.698	-7.6558	42.8543
RPMI-8402	GDSC1; GDSC2	-7.5467	-5.2214	-7.5851	42.5439
SUP-B15	GDSC1; GDSC2	-7.546	-3.6194	-7.854	43.2933
KMS-11	GDSC2	-7.5326	-5.523	-7.5507	42.329
TUR	GDSC1; GDSC2	-7.4416	-6.5021	-7.4417	41.3421
BV-173	GDSC1; GDSC2	-7.4406	-5.9727	-7.4434	41.3443
MOLP-8	GDSC1; GDSC2	-7.419	-3.7202	-7.691	42.0246
AMO1	GDSC1; GDSC2	-7.3854	-5.0638	-7.4296	40.962
WIL2 NS	GDSC1; GDSC2	-7.3729	-3.865	-7.6073	41.4813
RS4;11	GDSC1; GDSC2	-7.3395	-4.9282	-7.3945	40.5476
CESS	GDSC1; GDSC2	-7.3306	-5.6895	-7.3375	40.2597
NCI-H929	GDSC2	-7.3181	-5.5403	-7.3296	40.1552
U-698-M	GDSC1; GDSC2	-7.3076	-4.1454	-7.4777	40.6505
H9	GDSC1; GDSC2	-7.2983	-5.0011	-7.3439	40.1009
OCI-AML-3	GDSC1; GDSC2	-7.2812	-6.358	-7.2813	39.7321
Reh	GDSC1; GDSC2	-7.2067	-6.2258	-7.2069	38.9852
MY-M12	GDSC1; GDSC2	-7.2058	-5.3842	-7.2209	39.0457
VL51	GDSC1; GDSC2	-7.2047	-3.6653	-7.4708	39.9879
BC-3	GDSC1; GDSC2	-7.1592	-4.9233	-7.205	38.7149
KMS-12-BM	GDSC1; GDSC2	-7.1591	-5.5789	-7.166	38.5392
MC116	GDSC1; GDSC2	-7.1292	-5.5607	-7.1361	38.2395
BE-13	GDSC1; GDSC2	-7.1239	-4.04	-7.2994	38.888
MHH-CALL-2	GDSC2	-7.0621	-5.528	-7.0687	37.5653
MV4-11	GDSC1	-7.0597	-6.0592	-7.0607	38.6805
Loucy	GDSC1; GDSC2	-7.0158	-5.7337	-7.0178	37.0783
Namalwa	GDSC1; GDSC2	-6.9873	-5.4149	-6.9958	36.824
OCI-AML-5	GDSC1; GDSC2	-6.978	-5.6076	-6.9815	36.7065
KM-H2	GDSC1; GDSC2	-6.9709	-5.0758	-6.9956	36.7366
BC-1	GDSC1; GDSC2	-6.9696	-4.4997	-7.054	36.9952
GR-ST	GDSC1; GDSC2	-6.9639	-3.8596	-7.1637	37.4249
KCL-22	GDSC1; GDSC2	-6.9529	-4.7721	-7.0027	36.6734
P12-Ichikawa	GDSC1; GDSC2	-6.9516	-5.9874	-6.9518	36.425
P30/OHK	GDSC1; GDSC2	-6.9059	-4.6269	-6.9694	36.2671
Ku812	GDSC1; GDSC2	-6.8766	-3.5236	-7.1481	36.8662
OCI-AML-2	GDSC1; GDSC2	-6.8719	-5.9462	-6.8721	35.6257
NOMO-1	GDSC1; GDSC2	-6.8709	-5.8355	-6.8714	35.6165
EB2	GDSC1; GDSC2	-6.8303	-3.0744	-7.2211	36.8912
L-363	GDSC1; GDSC2	-6.8001	-5.6545	-6.8014	34.9105
PF-382	GDSC1; GDSC2	-6.7861	-4.2627	-6.8935	35.2746
RPMI-8226	GDSC1; GDSC2	-6.7537	-4.616	-6.8092	34.7089
HL-60	GDSC1; GDSC2	-6.6504	-6.0421	-6.6504	33.4017
Jiyoye	GDSC1; GDSC2	-6.6439	-2.8204	-7.0957	35.3704
Mono-Mac-6	GDSC1; GDSC2	-6.631	-1.7968	-7.4401	36.5914
DB	GDSC1; GDSC2	-6.6219	-2.7301	-7.1007	35.2723
CTB-1	GDSC1; GDSC2	-6.5963	-3.117	-6.9533	34.5202
LC4-1	GDSC1; GDSC2	-6.5881	-2.3345	-7.1977	35.4737
MM1.S	GDSC2	-6.554	-2.1031	-7.2437	35.4686
MOLT-16	GDSC1; GDSC2	-6.4662	-3.2974	-6.7601	32.9758
KOPN-8	GDSC1; GDSC2	-6.3718	-2.8884	-6.7781	32.5729
HT	GDSC1; GDSC2	-6.2457	-2.1517	-6.8944	32.4548
RPMI-8866	GDSC1; GDSC2	-6.2161	-3.7074	-6.3841	29.894
Kasumi-1	GDSC1; GDSC2	-6.1884	-2.2776	-6.7867	31.6906
Granta-519	GDSC1; GDSC2	-6.182	-2.7312	-6.6224	30.8953
MLMA	GDSC1; GDSC2	-6.1565	-2.6158	-6.6334	30.8221
Sc-1	GDSC1	-6.0911	-2.591	-6.7652	30.7295
ARH-77	GDSC1; GDSC2	-6.0417	-3.5412	-6.2332	28.2748
SCC-3	GDSC1; GDSC2	-6.0364	-4.9817	-6.0398	27.2573
PL-21	GDSC1; GDSC2	-6.0148	-2.593	-6.4877	29.4296
Karpas-1106P	GDSC2	-5.9893	-0.2934	-7.3873	33.2031
HDLM-2	GDSC1; GDSC2	-5.9657	-1.6055	-6.8067	30.7029
SU-DHL-4	GDSC1; GDSC2	-5.9607	-3.6645	-6.1159	27.2781
OCI-M1	GDSC1; GDSC2	-5.9547	-3.8942	-6.0615	26.9674
JURL-MK1	GDSC1; GDSC2	-5.9314	-3.1035	-6.2323	27.7418
HH [Human lymphoma]	GDSC1; GDSC2	-5.8579	1.0342	-7.8564	34.2301
MEG-01	GDSC1; GDSC2	-5.7763	-3.0668	-6.0742	26.1864
CA46	GDSC1; GDSC2	-5.7738	-0.2011	-7.2085	31.525
TALL-1 [Human adult T-ALL]	GDSC2	-5.761	-2.0949	-6.3966	27.7843
DND-41	GDSC1; GDSC2	-5.7544	-2.2192	-6.3422	27.4781
Karpas-422	GDSC1; GDSC2	-5.7468	-0.7434	-6.9411	30.2843
EJM	GDSC1; GDSC2	-5.686	-1.2244	-6.671	28.7823
A3/Kawakami	GDSC1; GDSC2	-5.684	-2.4306	-6.1882	26.3605
SU-DHL-8	GDSC1; GDSC2	-5.6819	-3.5324	-5.8431	24.5204
TK [Human B-cell lymphoma]	GDSC1; GDSC2	-5.6617	-2.4831	-6.1452	26.0335
Raji	GDSC1; GDSC2	-5.6232	-2.3691	-6.1456	25.8607
SUP-HD1	GDSC1; GDSC2	-5.5947	-0.2993	-6.9829	29.7878
MHH-CALL-4	GDSC2	-5.5518	-1.6336	-6.3593	26.6515
U266B1	GDSC1; GDSC2	-5.4734	-1.4957	-6.3348	26.181
GDM-1	GDSC1; GDSC2	-5.4088	-2.3098	-5.9382	23.7928
SU-DHL-1	GDSC1; GDSC2	-5.2862	1.9055	-7.7107	31.3466
L-540	GDSC1; GDSC2	-5.2104	-2.0862	-5.815	22.2562
EM-2	GDSC1; GDSC2	-5.1799	-1.5999	-5.9854	23.0685
Karpas-299	GDSC1; GDSC2	-5.1214	-2.2923	-5.6386	20.8893
WSU-NHL	GDSC1; GDSC2	-5.009	-2.2634	-5.5309	19.8035
VAL	GDSC1; GDSC2	-4.8897	-0.9443	-5.98	21.854
Daudi	GDSC1; GDSC2	-4.8275	-0.485	-6.1307	22.4338
LAMA-84	GDSC1; GDSC2	-4.7524	-1.113	-5.7654	20.1069
HEL	GDSC1; GDSC2	-4.3579	-1.0852	-5.3885	16.4074
DG-75	GDSC1; GDSC2	-4.3422	-1.5463	-5.1569	14.9587
KMOE-2	GDSC1; GDSC2	-4.2574	0.0441	-5.8364	18.6724
L-428	GDSC1; GDSC2	-3.8502	-1.1553	-4.8718	11.4598
THP-1	GDSC1; GDSC2	-3.8068	0.7273	-5.7636	16.721
YT	GDSC1; GDSC2	-3.7819	-2.1347	-4.3319	7.8707
IM-9	GDSC1; GDSC2	-3.7176	1.0869	-5.8641	17.01
KY821	GDSC1; GDSC2	-3.7108	1.1543	-5.8918	17.1458
JVM-3	GDSC1; GDSC2	-3.7004	-0.5186	-5.0503	12.0764
WSU-DLCL2	GDSC1; GDSC2	-3.6649	-2.7353	-3.9341	5.0038
NK-92MI	GDSC1; GDSC2	-3.6589	-1.4062	-4.5734	8.9599
LP-1	GDSC1; GDSC2	-3.6108	0.6874	-5.5721	14.9708
P31/FUJ	GDSC1; GDSC2	-3.5644	-1.4722	-4.4559	7.9172
EHEB	GDSC1	-3.5323	1.783	-6.4874	17.4598
KG-1	GDSC1; GDSC2	-3.4999	-1.2666	-4.5014	8.0011
K-562	GDSC1; GDSC2	-3.4824	-2.5553	-3.846	3.8159
HAL-01	GDSC1; GDSC2	-3.4583	0.2806	-5.2381	12.4816
RC-K8	GDSC1; GDSC2	-3.0325	0.4911	-4.993	9.7414
MN-60	GDSC1; GDSC2	-2.0014	2.1243	-5.0386	7.5301
ROS-50	GDSC1; GDSC2	-0.9165	6.6767	-6.4865	13.0741
L-1236	GDSC1; GDSC2	-0.5644	5.0491	-5.4937	7.3245
ME1	GDSC1; GDSC2	-0.1789	6.8436	-6.0852	9.6646
JVM-2	GDSC1; GDSC2	0.3511	4.6828	-4.8357	2.8343
RL	GDSC1; GDSC2	0.5453	11.1702	-7.6539	15.3107
SK-MM-2	GDSC1; GDSC2	0.7036	3.4384	-4.209	0.4824

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYSE-50	GDSC1; GDSC2	-8.1058	-6.6939	-8.1065	48.008
OACP4 C	GDSC2	-7.5859	-5.1562	-7.6317	42.9579
KYSE-220	GDSC1; GDSC2	-7.3116	-3.3827	-7.6595	41.2435
FLO-1	GDSC2	-6.9091	-3.4603	-7.1998	37.2554
ESO-51	GDSC2	-5.9707	-1.6865	-6.7795	30.6028
HCE-4	GDSC1; GDSC2	-5.4773	-2.1131	-6.0873	24.8996
OACM5.1 C	GDSC2	-5.1364	-0.2354	-6.5523	25.8501
ESO-26	GDSC2	-3.8851	0.7685	-5.8536	17.4958
TE-12	GDSC1; GDSC2	-1.3306	5.1882	-6.0535	11.7666
SK-GT-4	GDSC2	-0.5422	8.0586	-6.8955	14.2205
KYAE-1	GDSC2	0.0447	2.0366	-3.9613	0.2192

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; GDSC2	-5.4203	-0.7678	-6.5961	27.2541

Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-N-MC-IXC	GDSC1; GDSC2	-8.2202	-7.5648	-8.2202	49.1544
IMR-5	GDSC1; GDSC2	-7.5738	-6.5342	-7.5739	42.6681
SJNB-13	GDSC1	-7.5374	-4.9281	-7.6493	45.0085
SJNB-14	GDSC1; GDSC2	-6.6036	-3.2424	-6.9253	34.4373
NB69	GDSC1; GDSC2	-6.4467	-3.2877	-6.7415	32.7892
SJNB-12	GDSC1; GDSC2	-6.3597	-2.8382	-6.7808	32.5236
GI-ME-N	GDSC1; GDSC2	-6.0634	0.1773	-7.6719	34.5524
CHP-134	GDSC2	-5.8575	-2.968	-6.1933	27.1903
KP-N-YS	GDSC1; GDSC2	-5.7034	-2.905	-6.0457	25.6979
CHP-212	GDSC1; GDSC2	-5.5498	-0.5176	-6.8394	28.9558
NB1	GDSC1; GDSC2	-5.2733	-0.1344	-6.7352	27.2944
NH-12	GDSC1; GDSC2	-5.0992	-2.5706	-5.5084	20.0604
SJNB-17	GDSC1; GDSC2	-5.0044	-1.729	-5.7481	21.0186
KP-N-YN	GDSC1	-4.845	-0.4904	-6.4813	22.5982
MHH-NB-11	GDSC1; GDSC2	-4.8243	-2.1309	-5.3906	18.231
SK-N-BE(2)-M17	GDSC1; GDSC2	-4.553	-1.885	-5.2155	16.117
SK-N-SH	GDSC1; GDSC2	-4.3131	5.3209	-8.4948	30.4072
SJNB-10	GDSC1; GDSC2	-4.2581	-1.9072	-4.9069	13.1336
KP-N-RT-BM-1	GDSC2	-4.1986	1.2997	-6.3986	21.5324
SJNB-5	GDSC1; GDSC2	-4.197	-0.8737	-5.3345	15.5003
CHP-126	GDSC1; GDSC2	-4.1962	1.23	-6.3621	21.3345
TGW	GDSC1; GDSC2	-4.0518	-2.3745	-4.4872	9.816
Kelly	GDSC1; GDSC2	-3.9256	-1.2667	-4.8876	11.8147
NB(TU)1	GDSC1; GDSC2	-3.7251	-0.4117	-5.1253	12.6199
GOTO	GDSC1; GDSC2	-3.7042	1.4082	-6.0127	17.8046
SiMa	GDSC1; GDSC2	-3.5806	-0.0579	-5.1742	12.4645
SK-N-DZ	GDSC1; GDSC2	-3.4557	-0.9019	-4.6451	8.7723
SK-N-FI	GDSC1; GDSC2	-3.0423	-0.4343	-4.5398	6.9332
SJNB-6	GDSC1; GDSC2	-2.9363	3.1814	-6.2581	16.8286
SJNB-7	GDSC1; GDSC2	-2.4181	3.0471	-5.7881	12.862
SK-N-AS	GDSC1; GDSC2	-2.2837	2.7423	-5.5383	11.1013
LA-N-6	GDSC1; GDSC2	-2.0061	3.6055	-5.7597	11.6962

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuCC-T1	GDSC1; GDSC2	-7.0802	-3.3475	-7.4165	39.0495

Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC1806	GDSC1; GDSC2	-8.6434	-5.4031	-8.7213	53.1757
CAL-85-1	GDSC1; GDSC2	-8.478	-6.5469	-8.483	51.73
AU565	GDSC1; GDSC2	-8.4321	-6.7709	-8.4339	51.2779
MRK-nu-1	GDSC1; GDSC2	-7.6743	-5.7365	-7.6869	43.7245
MDA-MB-468	GDSC1; GDSC2	-7.6545	-6.3723	-7.6552	43.4809
JIMT-1	GDSC1; GDSC2	-7.5892	-6.2269	-7.5905	42.8282
HCC1187	GDSC1; GDSC2	-7.5862	-5.7757	-7.5954	42.8304
MDA-MB-361	GDSC1; GDSC2	-7.3826	-4.6451	-7.4748	41.1116
HCC38	GDSC1; GDSC2	-7.3433	-5.5205	-7.3563	40.414
HCC1599	GDSC1; GDSC2	-7.2956	-5.9852	-7.2971	39.8836
HCC1954	GDSC1; GDSC2	-7.1224	-5.1976	-7.145	38.2443
EFM-192A	GDSC1; GDSC2	-6.9132	-4.6964	-6.9691	36.3049
CAL-51	GDSC1; GDSC2	-6.7418	-3.8901	-6.9157	35.1368
MCF-7	GDSC1; GDSC2	-6.7321	-4.5893	-6.7895	34.5018
OCUB-M	GDSC1; GDSC2	-6.5835	-1.6936	-7.4286	36.2981
CAL-148	GDSC1; GDSC2	-6.1868	-3.5328	-6.3935	29.7971
HCC1395	GDSC1; GDSC2	-6.0334	-2.5698	-6.5159	29.6576
EFM-19	GDSC1; GDSC2	-5.9785	-1.51	-6.8588	30.9968
MDA-MB-415	GDSC1; GDSC2	-5.2329	-1.248	-6.1924	24.4074
HCC1569	GDSC1; GDSC2	-5.1837	2.8327	-8.0614	32.1272
HCC2157	GDSC1; GDSC2	-4.9731	-2.3876	-5.4436	19.1551
BT-20	GDSC1; GDSC2	-4.9727	-2.0865	-5.5645	19.8433
HCC70	GDSC1; GDSC2	-4.9711	-0.8591	-6.1006	22.84
CAMA-1	GDSC1; GDSC2	-4.8354	5.8548	-9.2255	34.108
BT-549	GDSC1; GDSC2	-4.6619	0.5893	-6.482	23.6366
COLO 824	GDSC1; GDSC2	-4.5943	-0.0403	-6.1146	21.4539
MDA-MB-231	GDSC1; GDSC2	-4.4476	0.7412	-6.354	22.187
BT-474	GDSC1; GDSC2	-4.2818	2.7499	-7.1907	25.566
DU4475	GDSC1; GDSC2	-4.1188	-0.931	-5.2326	14.6062
CAL-120	GDSC1; GDSC2	-4.1018	2.4323	-6.8723	23.5243
HCC1500	GDSC1; GDSC2	-4.0233	2.4831	-6.8278	23.0509
HCC2218	GDSC1; GDSC2	-3.7307	4.7013	-7.6791	25.7321
MDA-MB-330	GDSC1; GDSC2	-3.6	4.7159	-7.5749	24.9171
Hs 578T	GDSC1; GDSC2	-3.5486	1.4263	-5.8875	16.6089
MDA-MB-436	GDSC1; GDSC2	-3.4867	2.2799	-6.2613	18.4733
HDQ-P1	GDSC1; GDSC2	-3.0792	2.7363	-6.1512	16.6644
MDA-MB-453	GDSC1; GDSC2	-2.98	5.863	-7.6326	23.3107
ZR-75-30	GDSC1; GDSC2	-2.8618	7.8858	-8.5471	26.2644
MFM-223	GDSC1; GDSC2	-2.7919	0.6228	-4.8719	8.3584
MDA-MB-157	GDSC1; GDSC2	-2.5253	1.9105	-5.3076	10.3394
Evsa-T	GDSC1; GDSC2	-2.1236	4.8194	-6.4422	15.6202
YMB-1-E	GDSC2	-1.657	7.8438	-7.5853	19.6716
MDA-MB-175-VII	GDSC1; GDSC2	-0.4495	6.1126	-5.9143	9.2964
HCC1428	GDSC1; GDSC2	-0.2246	8.8515	-7.0611	14.3206
UACC-893	GDSC1; GDSC2	-0.178	7.9112	-6.5843	12.0685
HCC1937	GDSC1; GDSC2	-0.1662	10.2816	-7.7072	16.8908
T-47D	GDSC1; GDSC2	-0.1379	9.2693	-7.2026	14.7618
HCC1419	GDSC1; GDSC2	0.0281	11.3223	-8.0751	17.9067
UACC-812	GDSC1; GDSC2	0.1295	5.1967	-5.1652	4.6071
HCC1143	GDSC2	0.6166	9.3001	-6.7306	11.3009
BT-483	GDSC1; GDSC2	1.7821	10.493	-6.5824	8.8164

Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KS-1 [Human Krukenberg tumour]	GDSC1; GDSC2	-8.1738	-2.2687	-8.9379	49.044
SK-MG-1	GDSC1; GDSC2	-8.0433	-5.9615	-8.0562	47.4065
Hs 683	GDSC1; GDSC2	-7.9652	-6.4718	-7.9667	46.6003
MOG-G-UVW	GDSC1; GDSC2	-7.8008	-5.7785	-7.8149	44.9933
ONS-76	GDSC1; GDSC2	-7.7352	-4.5385	-7.869	44.6562
GI-1	GDSC1; GDSC2	-7.4719	-4.2633	-7.633	42.2055
DBTRG-05MG	GDSC1; GDSC2	-7.3982	-3.8571	-7.6366	41.7333
Becker	GDSC1; GDSC2	-7.367	-4.8954	-7.4271	40.8401
YKG-1	GDSC1; GDSC2	-7.3549	-5.2259	-7.3846	40.6002
H4	GDSC1; GDSC2	-7.3103	-4.5254	-7.4148	40.4454
Daoy	GDSC1; GDSC2	-6.9659	-5.5254	-6.9709	36.5921
KNS-42	GDSC1; GDSC2	-6.9107	-3.9435	-7.0879	36.8115
U-251MG	GDSC1; GDSC2	-6.8549	-4.6818	-6.909	35.7142
GaMG	GDSC1; GDSC2	-6.782	-5.0549	-6.801	34.8164
SF539	GDSC1; GDSC2	-6.5543	-4.8188	-6.5802	32.5665
8-MG-BA	GDSC1; GDSC2	-6.4424	-1.2476	-7.4545	35.6549
D-566MG	GDSC1; GDSC2	-6.4072	-3.2776	-6.7012	32.3984
PFSK-1	GDSC1; GDSC2	-6.0077	-3.1138	-6.3124	28.5166
D-247MG	GDSC1; GDSC2	-5.9642	-3.2046	-6.2384	27.9294
A-172	GDSC1; GDSC2	-5.9473	-1.5574	-6.8067	30.6152
SF295	GDSC1; GDSC2	-5.926	-2.9975	-6.2586	27.8513
M059J	GDSC1; GDSC2	-5.9219	-1.6407	-6.7463	30.2204
T98G	GDSC1; GDSC2	-5.9088	-3.4181	-6.1193	27.0478
YH-13	GDSC1; GDSC2	-5.8388	-2.9585	-6.1758	27.0115
MOG-G-CCM	GDSC1; GDSC2	-5.8187	-1.55	-6.6741	29.4034
NMC-G1	GDSC1; GDSC2	-5.6831	-2.95	-6.0092	25.4103
SF268	GDSC1; GDSC2	-5.6276	-1.7974	-6.3721	27.0543
D-423MG	GDSC1; GDSC2	-5.3629	-1.509	-6.2141	25.0744
KALS-1	GDSC1; GDSC2	-5.2698	1.1632	-7.3402	29.8937
LNZTA3WT4	GDSC1; GDSC2	-5.144	-3.6143	-5.2389	18.7774
D-336MG	GDSC1; GDSC2	-5.1281	-0.6505	-6.3532	24.8127
LN-229	GDSC1; GDSC2	-4.8008	-2.3721	-5.267	17.4196
U-87MG ATCC	GDSC1; GDSC2	-4.6883	-1.3009	-5.6152	18.9931
AM-38	GDSC1; GDSC2	-4.6676	-0.6124	-5.914	20.6214
D-502MG	GDSC1; GDSC2	-4.5231	-1.1947	-5.4994	17.682
D283 Med	GDSC1; GDSC2	-4.0624	1.275	-6.2634	20.3539
D-392MG	GDSC1; GDSC2	-3.8735	1.3919	-6.1529	19.1266
D-542MG	GDSC1; GDSC2	-3.8377	-0.5619	-5.1522	13.1541
SW1088	GDSC1; GDSC2	-3.5947	6.8806	-8.6522	28.6629
SF126	GDSC1; GDSC2	-3.5347	1.1893	-5.7572	15.8188
LN-18	GDSC1; GDSC2	-3.2317	0.405	-5.1108	11.0282
SW1783	GDSC1; GDSC2	-2.7534	2.9206	-5.983	14.8316
KINGS-1	GDSC1; GDSC2	-2.579	9.1922	-8.9711	26.8338
U-118MG	GDSC1; GDSC2	-2.5737	3.9034	-6.3315	16.217
D-245MG	GDSC2	-2.103	3.9611	-6.0043	13.2737
SNB-75	GDSC1; GDSC2	-1.9487	8.9544	-8.3566	23.2747
DK-MG	GDSC1; GDSC2	-1.6166	8.1408	-7.7016	20.0418
Onda 10	GDSC1; GDSC2	-1.3652	8.581	-7.7318	19.571
GB-1	GDSC1; GDSC2	-1.2979	3.389	-5.1779	6.9278
Onda 11	GDSC1; GDSC2	-1.1169	7.585	-7.0649	16.2062
D-263MG	GDSC1; GDSC2	-0.6213	7.6817	-6.7683	13.8001
LN-405	GDSC1; GDSC2	-0.6018	4.9096	-5.4524	7.1718
42-MG-BA	GDSC1; GDSC2	-0.0673	8.9287	-6.9934	13.7161
CAS-1	GDSC1; GDSC2	-0.0598	20.9262	-12.8463	30.0442
KNS-81-FD	GDSC1; GDSC2	0.4883	11.6248	-7.908	16.3968

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC1; GDSC2	-7.502	-5.2756	-7.5343	42.0772
TGBC24TKB	GDSC1; GDSC2	-5.0373	-3.197	-5.2295	18.233
TGBC1TKB	GDSC1; GDSC2	0.2127	4.7326	-4.9245	3.3768

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ESS-1	GDSC1; GDSC2	-7.6865	-5.9706	-7.6923	43.822
MFE-319	GDSC1; GDSC2	-7.57	-6.3033	-7.5707	42.6334
RL95-2	GDSC1; GDSC2	-7.1115	-5.0299	-7.1456	38.1872
MFE-296	GDSC1; GDSC2	-6.6234	-3.3918	-6.9061	34.4587
AN3-CA	GDSC1; GDSC2	-6.5032	-4.2805	-6.5868	32.3402
EN	GDSC1; GDSC2	-3.4155	5.6956	-7.9089	25.6343
MFE-280	GDSC1; GDSC2	-1.0773	5.7739	-6.1625	11.7934
KLE	GDSC1; GDSC2	-0.2213	7.0062	-6.1874	10.2448

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
786-O	GDSC1; GDSC2	-7.944	-5.8819	-7.9576	46.4198
SW13	GDSC1; GDSC2	-7.3174	-6.176	-7.3178	40.097
RXF 393L	GDSC1; GDSC2	-6.4408	1.0083	-8.428	38.4696
769-P	GDSC1; GDSC2	-5.7455	-0.1105	-7.2204	31.446
BFTC-909	GDSC1; GDSC2	-5.6738	-2.3146	-6.2201	26.4807
VMRC-RCZ	GDSC1; GDSC2	-5.5396	-3.3882	-5.7243	23.2213
KTCTL-195	GDSC2	-5.5141	0.2431	-7.1491	30.1416
KTCTL-140	GDSC2	-5.4683	-2.3288	-5.9945	24.361
KTCTL-21	GDSC2	-4.982	-0.7415	-6.1653	23.2327
BB65-RCC	GDSC1; GDSC2	-4.6363	-0.2876	-6.0371	21.1873
OS-RC-2	GDSC1; GDSC2	-4.5216	1.4314	-6.7599	24.4767
ACHN	GDSC1; GDSC2	-4.4641	-1.3704	-5.3594	16.6296
HA7-RCC	GDSC1; GDSC2	-4.3633	2.8025	-7.2901	26.2702
SN12C	GDSC1; GDSC2	-3.8092	7.4351	-9.1117	30.6137
NCC010	GDSC2	-3.566	-1.2346	-4.5754	8.6744
CAL-54	GDSC1; GDSC2	-3.2734	-0.4348	-4.7252	8.7394
KTCTL-13	GDSC2	-3.2478	0.1069	-4.975	10.2317
Caki-1	GDSC1; GDSC2	-3.1901	-1.5878	-4.0817	4.4409
KMRC-20	GDSC1; GDSC2	-3.0233	-0.7394	-4.3735	5.8384
KMRC-1	GDSC1; GDSC2	-3.0209	2.4054	-5.9388	15.3289
LB996-RCC	GDSC1; GDSC2	-2.9974	0.2813	-4.8608	8.8247
KTCTL-1M	GDSC2	-2.8883	0.0485	-4.6608	7.2916
LB1047-RCC	GDSC1; GDSC2	-2.5182	1.16	-4.9335	8.0639
UO-31	GDSC1; GDSC2	-1.9098	1.7314	-4.7909	5.8902
NCC021	GDSC2	-1.8071	2.3539	-5.0184	7.0085
LB2241-RCC	GDSC1; GDSC2	-1.3215	5.837	-6.3604	13.3211
SW156	GDSC1; GDSC2	-1.2276	2.5603	-4.7554	4.4798
KTCTL-26A	GDSC2	-0.7558	1.8436	-4.2077	1.2844
TK-10	GDSC1; GDSC2	-0.6348	6.0634	-6.0088	10.1233
VMRC-RCW	GDSC1; GDSC2	-0.1766	4.6344	-5.0856	4.6319
RCC10RGB	GDSC1; GDSC2	-0.142	2.6372	-4.2488	0.9874
A-498	GDSC1; GDSC2	-0.1002	10.3965	-7.7173	16.7985
A-704	GDSC1; GDSC2	0.2405	2.6972	-4.1198	0.4544

Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO205	GDSC1; GDSC2	-9.0309	-6.8123	-9.038	56.982
HT-29	GDSC1; GDSC2	-8.4944	-7.12	-8.4947	51.7232
SNU-175	GDSC2	-8.4228	-6.9867	-8.4233	51.0073
KM12	GDSC1; GDSC2	-8.1765	-5.8847	-8.1961	48.5694
RKO	GDSC1; GDSC2	-8.1074	-5.9453	-8.1225	47.8813
SW48	GDSC1; GDSC2	-7.7254	-5.3932	-7.7584	44.1471
HCC2998	GDSC1; GDSC2	-7.6709	-5.2233	-7.715	43.6428
LoVo	GDSC1; GDSC2	-7.3291	-3.8898	-7.5541	40.9001
GP5d	GDSC1; GDSC2	-7.1888	-5.5886	-7.1959	38.7028
SW620	GDSC1; GDSC2	-7.0885	-4.0879	-7.2516	38.3639
HCT 116	GDSC1; GDSC2	-6.9629	-4.0546	-7.1221	37.1217
SNU-283	GDSC2	-6.7685	-4.1278	-6.8979	35.2001
SNU-C5	GDSC2	-6.7164	-2.3313	-7.3374	36.5744
SK-CO-1	GDSC2	-6.5736	-2.3214	-7.1866	35.2404
NCI-H508	GDSC2	-6.0982	-3.0835	-6.4201	29.3955
MDST8	GDSC1; GDSC2	-6.084	-3.0329	-6.4199	29.3259
SNU-C2B	GDSC1; GDSC2	-6.0498	-2.464	-6.5706	29.9008
SW948	GDSC1; GDSC2	-5.7029	-2.3125	-6.252	26.6879
DiFi	GDSC2	-5.4905	-1.8245	-6.2166	25.556
SNU-1040	GDSC2	-5.4492	2.6485	-8.2235	33.5814
SNU-407	GDSC2	-5.3808	-0.6763	-6.5968	27.0023
LS180	GDSC1; GDSC2	-4.435	0.1613	-6.0602	20.5
CaR-1	GDSC1; GDSC2	-4.4081	0.161	-6.0347	20.2622
LS513	GDSC1; GDSC2	-4.1567	0.9182	-6.1724	20.1259
SW626	GDSC1; GDSC2	-3.9797	2.4067	-6.7513	22.5413
HCT 15	GDSC1; GDSC2	-3.9243	-0.0082	-5.5042	15.5282
CCK-81	GDSC1; GDSC2	-3.8542	-1.7299	-4.5958	9.7243
LS411N	GDSC1; GDSC2	-3.8227	3.5486	-7.1829	23.9302
SNU-81	GDSC2	-3.8178	1.8995	-6.3566	19.9676
T84	GDSC1; GDSC2	-3.5226	-0.6685	-4.8193	10.0386
HT-55	GDSC1; GDSC2	-3.4676	-0.7402	-4.7361	9.3492
COLO 320HSR	GDSC1; GDSC2	-3.2783	-0.7301	-4.5817	7.8209
HT115	GDSC1; GDSC2	-3.0759	-1.1149	-4.2277	5.0404
NCI-H747	GDSC1; GDSC2	-3.0536	4.6906	-7.1068	21.2509
SNU-C1	GDSC1; GDSC2	-3.013	1.6474	-5.554	13.0493
CW-2	GDSC1; GDSC2	-2.7478	1.2103	-5.1291	9.7924
LS1034	GDSC1; GDSC2	-2.4357	3.0101	-5.7831	12.8376
NCI-H716	GDSC1; GDSC2	-1.7402	2.9974	-5.2805	8.3558
SW837	GDSC1; GDSC2	-1.6893	2.3191	-4.9256	6.2194
C2BBe1	GDSC1; GDSC2	-1.6806	3.4784	-5.4706	9.3096
CL-11	GDSC1; GDSC2	-1.601	4.9647	-6.1334	12.7444
SW1463	GDSC1; GDSC2	-0.7943	7.3865	-6.7442	14.009
SW1417	GDSC1; GDSC2	-0.7822	8.4209	-7.2351	16.1828
COLO 678	GDSC1; GDSC2	-0.2895	5.0175	-5.3178	5.9459
SW1116	GDSC2	0.0375	4.1738	-4.7785	2.906
RCM-1 [Human ESC]	GDSC1; GDSC2	0.3888	6.4914	-5.5901	6.284
LS123	GDSC1; GDSC2	0.8662	11.8104	-7.7472	15.0576

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1; GDSC2	-3.4064	0.0565	-5.082	11.3619

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-398	GDSC1; GDSC2	-9.0042	-7.9194	-9.0042	57.0214
SK-HEP-1	GDSC1; GDSC2	-7.4958	-5.4021	-7.5193	41.982
JHH-7	GDSC1; GDSC2	-7.1026	-5.4712	-7.1117	37.9832
SNU-423	GDSC1; GDSC2	-6.8926	-3.9598	-7.0649	36.6136
JHH-1	GDSC1; GDSC2	-6.4874	-3.1345	-6.8294	33.4009
HLE	GDSC1; GDSC2	-6.4067	-4.5516	-6.4494	31.1704
SNU-387	GDSC1; GDSC2	-5.7239	-0.1469	-7.1822	31.1953
Hep 3B2.1-7	GDSC1; GDSC2	-5.7173	-0.9408	-6.8249	29.635
Huh-7	GDSC1; GDSC2	-4.5555	3.5261	-7.8214	29.0038
JHH-4	GDSC1; GDSC2	-4.0031	-1.2372	-4.975	12.6231
JHH-6	GDSC1; GDSC2	-3.5553	0.3599	-5.3607	13.5274
SNU-475	GDSC1	-3.4016	-0.1248	-5.4387	9.667
HuH-1	GDSC1; GDSC2	-3.141	0.052	-4.8606	9.2151
JHH-2	GDSC1; GDSC2	-2.8904	0.3206	-4.7972	8.1472
SNU-449	GDSC1; GDSC2	-0.4113	7.4826	-6.5336	12.2786
Hep-G2/C3A	GDSC1; GDSC2	-0.2012	7.7063	-6.5027	11.728

Cancer Drug Sensitivity Data Curated from 186 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H3122	GDSC1; GDSC2	-8.83	-7.6101	-8.83	55.272
NCI-H1703	GDSC1; GDSC2	-8.608	-7.366	-8.6081	53.045
HCC44	GDSC1; GDSC2	-8.6075	-6.4135	-8.6174	52.9991
NCI-H2122	GDSC1; GDSC2	-8.5803	-6.9652	-8.5814	52.7617
LCLC-97TM1	GDSC1; GDSC2	-8.5684	-6.2008	-8.5848	52.597
HOP-62	GDSC1; GDSC2	-8.441	-5.3043	-8.5181	51.2895
NCI-H847	GDSC1; GDSC2	-8.4098	-6.707	-8.412	51.0541
NCI-H520	GDSC1; GDSC2	-8.2998	-6.2584	-8.3085	49.9534
DMS 273	GDSC1; GDSC2	-8.2358	-6.8574	-8.2363	49.3116
SBC-5	GDSC1; GDSC2	-8.09	-7.0967	-8.09	47.8483
NCI-H522	GDSC1; GDSC2	-7.9963	-5.1814	-8.0613	47.0325
HCC15	GDSC1; GDSC2	-7.9703	-6.2913	-7.9737	46.6567
NCI-H292	GDSC1; GDSC2	-7.9645	-3.4319	-8.3589	47.1501
NCI-H2030	GDSC1; GDSC2	-7.9266	-6.0013	-7.9357	46.2346
EPLC-272H	GDSC1; GDSC2	-7.9149	-3.9487	-8.1782	46.5592
NCI-H211	GDSC1; GDSC2	-7.9119	-6.1305	-7.9175	46.078
A-427	GDSC1; GDSC2	-7.8618	-5.2051	-7.9171	45.703
NCI-H1355	GDSC1; GDSC2	-7.8608	-4.6985	-7.9787	45.8227
NCI-H2342	GDSC1; GDSC2	-7.7808	-6.521	-7.7813	44.7476
Lu-135	GDSC1; GDSC2	-7.732	-5.3017	-7.7723	44.3869
NCI-H64	GDSC1; GDSC2	-7.701	-4.9094	-7.7795	44.1883
NCI-H1437	GDSC1; GDSC2	-7.6577	-6.5556	-7.6578	43.5104
NCI-H2369	GDSC1; GDSC2	-7.6254	-6.0596	-7.6288	43.2
NCI-H460	GDSC1; GDSC2	-7.607	-6.2582	-7.6081	43.0061
COR-L279	GDSC2	-7.6012	-4.977	-7.6658	43.1692
EMC-BAC-2	GDSC2	-7.5589	-2.5534	-8.1765	44.0481
SBC-3	GDSC1; GDSC2	-7.5504	-5.8673	-7.5565	42.4594
COR-L321	GDSC2	-7.4972	-4.9147	-7.5627	42.1468
NCI-H1944	GDSC1; GDSC2	-7.4953	-5.0159	-7.5499	42.0909
Calu-6	GDSC1; GDSC2	-7.4509	-4.0898	-7.644	42.0994
EMC-BAC-1	GDSC2	-7.4387	-3.0051	-7.9051	42.7008
NCI-H2110	GDSC1; GDSC2	-7.3143	-6.1542	-7.3149	40.0666
IA-LM	GDSC1; GDSC2	-7.3	-5.4286	-7.3158	39.9926
NCI-H1770	GDSC1; GDSC2	-7.2875	-5.6326	-7.2953	39.8317
NCI-H358	GDSC1; GDSC2	-7.2762	-5.5319	-7.287	39.732
PC-14	GDSC1; GDSC2	-7.2539	-4.9099	-7.3061	39.6852
HARA [Human squamous cell lung carcinoma]	GDSC1; GDSC2	-7.2513	-5.0339	-7.2916	39.6107
NCI-H1648	GDSC1; GDSC2	-7.2204	-4.5872	-7.3096	39.5014
NCI-H69	GDSC1; GDSC2	-7.143	-3.7565	-7.3819	39.3053
LB647-SCLC	GDSC1; GDSC2	-7.086	-2.8827	-7.5576	39.5485
ChaGo-K-1	GDSC1; GDSC2	-7.0603	-1.9399	-7.848	40.2365
NCI-H526	GDSC1; GDSC2	-7.0479	-5.474	-7.0557	37.4283
EBC-1	GDSC1; GDSC2	-7.0091	-4.4991	-7.0963	37.3998
RERF-LC-KJ	GDSC1; GDSC2	-6.972	-5.2473	-6.9869	36.7012
LK-2	GDSC1; GDSC2	-6.8972	-5.4278	-6.9035	35.9096
LC-2/ad	GDSC1; GDSC2	-6.8949	0.4192	-8.6292	41.1087
Lu-99A	GDSC1; GDSC2	-6.8627	-2.9247	-7.3015	37.3757
SK-MES-1	GDSC1; GDSC2	-6.8232	-3.1624	-7.1877	36.7223
COR-L23	GDSC1; GDSC2	-6.7701	-3.9737	-6.9292	35.3502
NCI-H2009	GDSC1; GDSC2	-6.7608	-4.8387	-6.7945	34.6753
NCI-H510A	GDSC1; GDSC2	-6.7539	-4.7746	-6.793	34.632
NCI-H3255	GDSC1; GDSC2	-6.7513	-2.3771	-7.3593	36.9614
NCI-H1048	GDSC1; GDSC2	-6.6891	-5.3804	-6.6933	33.8112
RERF-LC-MS	GDSC1; GDSC2	-6.6212	-4.6668	-6.6637	33.3193
A-549	GDSC1; GDSC2	-6.6038	-3.332	-6.9008	34.3314
LCLC-103H	GDSC1; GDSC2	-6.5496	-1.728	-7.3792	35.9446
NCI-H1781	GDSC1; GDSC2	-6.516	-3.4165	-6.7824	33.3363
NCI-H2804	GDSC1; GDSC2	-6.515	-2.7529	-6.9771	34.1914
ABC-1	GDSC1; GDSC2	-6.4242	-5.0737	-6.4321	31.1715
NCI-H1734	GDSC1; GDSC2	-6.4154	-3.4659	-6.6597	32.2448
NCI-H841	GDSC1; GDSC2	-6.4033	-4.7888	-6.4252	31.0322
NCI-H1975	GDSC1; GDSC2	-6.3937	-2.6732	-6.8714	33.1033
NCI-H446	GDSC1; GDSC2	-6.3647	-2.6851	-6.836	32.7982
NCI-H2087	GDSC1; GDSC2	-6.3636	-4.4029	-6.4207	30.8108
NCI-H2869	GDSC1; GDSC2	-6.285	-3.028	-6.6404	31.4932
NCI-H2170	GDSC1; GDSC2	-6.2561	-3.0429	-6.6044	31.177
NCI-H1436	GDSC1; GDSC2	-6.1533	-3.2624	-6.4284	29.807
COR-L311	GDSC2	-6.1275	-2.614	-6.6026	30.5334
NCI-H187	GDSC1	-6.0385	-2.7265	-6.6554	29.7904
NCI-H1299	GDSC1; GDSC2	-5.988	-2.8223	-6.3818	28.7739
CAL-12T	GDSC1; GDSC2	-5.9631	-2.7959	-6.3634	28.5623
LXF 289	GDSC1; GDSC2	-5.952	-3.59	-6.1237	27.2771
COR-L303	GDSC2	-5.8417	-1.3474	-6.7819	30.009
NCI-H647	GDSC1; GDSC2	-5.8092	-2.3272	-6.3607	27.8258
NCI-H810	GDSC1; GDSC2	-5.6202	-1.9028	-6.3221	26.7661
NCI-H1755	GDSC1; GDSC2	-5.5794	-1.2908	-6.5319	27.6364
IST-SL1	GDSC1; GDSC2	-5.521	0.3872	-7.2225	30.4715
NCI-H1915	GDSC1; GDSC2	-5.5008	-2.4279	-5.9923	24.4937
NCI-H1963	GDSC1	-5.472	-0.6997	-6.9771	28.5002
HCC366	GDSC2	-5.3996	3.8834	-8.7748	34.9863
NCI-H838	GDSC1; GDSC2	-5.3937	-1.1625	-6.395	26.1426
NCI-H2591	GDSC1; GDSC2	-5.3386	3.7868	-8.6707	34.4889
NCI-H1792	GDSC1; GDSC2	-5.313	-3.6303	-5.4191	20.5312
Calu-3	GDSC1; GDSC2	-5.2903	-1.7682	-6.0294	23.776
NCI-H2595	GDSC1; GDSC2	-5.28	1.7185	-7.6151	30.9785
HCC33	GDSC1; GDSC2	-5.2793	-0.428	-6.6066	26.7066
Lu-65	GDSC1; GDSC2	-5.1307	-1.1957	-6.1107	23.5446
NCI-H650	GDSC1; GDSC2	-5.0621	0.232	-6.6974	26.2512
NCI-H1793	GDSC1; GDSC2	-5.0614	-1.1419	-6.064	23.0072
NCI-H1581	GDSC1; GDSC2	-4.9525	-1.7012	-5.7064	20.569
IST-SL2	GDSC1; GDSC2	-4.9393	-0.0492	-6.4449	24.5203
NCI-H209	GDSC1; GDSC2	-4.8536	-1.0954	-5.8749	21.1253
NCI-H2347	GDSC1; GDSC2	-4.8503	-1.7404	-5.584	19.4543
NCI-H1304	GDSC1	-4.815	1.7949	-7.5812	28.4078
Lu-134-A	GDSC1; GDSC2	-4.7825	-0.5395	-6.0609	21.8788
LOU-NH91	GDSC1; GDSC2	-4.7778	-2.6007	-5.1528	16.6665
NCI-H661	GDSC1; GDSC2	-4.7399	0.9544	-6.7323	25.1588
COLO 668	GDSC1; GDSC2	-4.7264	-2.4137	-5.1717	16.56
NCI-H226	GDSC1; GDSC2	-4.692	1.6224	-7.0117	26.262
COR-L105	GDSC1; GDSC2	-4.691	6.7902	-9.5598	34.4107
SW1271	GDSC1; GDSC2	-4.6214	-1.2704	-5.5621	18.4248
HCC78	GDSC1; GDSC2	-4.6121	-0.3034	-6.0062	20.9251
NCI-H1623	GDSC1; GDSC2	-4.5294	-1.9726	-5.1527	15.6519
NCI-H1876	GDSC1; GDSC2	-4.5223	-1.8856	-5.1839	15.8091
NCI-H2722	GDSC1; GDSC2	-4.5163	2.0207	-7.0439	25.7583
Lu-139	GDSC1; GDSC2	-4.5141	-1.0127	-5.5754	18.0947
NCI-H2081	GDSC1; GDSC2	-4.4971	0.5482	-6.3063	22.1188
NCI-H2141	GDSC1; GDSC2	-4.4782	-0.333	-5.8631	19.6231
NCI-H82	GDSC1; GDSC2	-4.4296	-2.2087	-4.947	14.0386
NCI-H1568	GDSC1; GDSC2	-4.4274	1.0259	-6.4742	22.7314
NCI-H441	GDSC1; GDSC2	-4.3962	0.1215	-6.0043	20.117
NCI-H1694	GDSC1	-4.3287	-0.1076	-6.2051	18.5742
Ms-1	GDSC1; GDSC2	-4.292	-1.1045	-5.3154	15.7273
SBC-1	GDSC1; GDSC2	-4.2741	-1.0762	-5.3115	15.6394
NCI-H2171	GDSC1; GDSC2	-4.2687	0.2237	-5.9346	19.2697
COR-L32	GDSC2	-4.2231	0.0404	-5.8027	18.358
NCI-H748	GDSC1; GDSC2	-4.1784	1.4937	-6.4761	21.8593
NCI-H290	GDSC1; GDSC2	-4.1691	2.5034	-6.9676	24.1924
NCI-H2405	GDSC1; GDSC2	-4.1632	-0.3745	-5.5444	16.6377
NCI-H524	GDSC1; GDSC2	-4.1215	-2.1243	-4.6707	11.189
UMC-11	GDSC1; GDSC2	-4.1163	-0.7768	-5.3048	15.036
NCI-H23	GDSC1; GDSC2	-4.1107	-0.7047	-5.3346	15.1968
NCI-H1651	GDSC1; GDSC2	-4.1066	-1.3803	-5.0049	13.1725
NCI-H2228	GDSC1; GDSC2	-3.9361	2.9042	-6.9606	23.3755
NCI-H835	GDSC2	-3.8113	2.4149	-6.6077	21.285
COR-L88	GDSC1; GDSC2	-3.7606	2.3847	-6.5486	20.8256
CPC-N	GDSC1; GDSC2	-3.7447	0.4744	-5.583	15.4608
NCI-H250	GDSC2	-3.7311	0.4768	-5.5722	15.3529
NCI-H1092	GDSC1; GDSC2	-3.7046	0.8796	-5.7495	16.3092
NCI-H1836	GDSC1; GDSC2	-3.6511	1	-5.763	16.2172
VMRC-LCD	GDSC2	-3.6158	2.179	-6.321	19.1926
NCI-H1155	GDSC1; GDSC2	-3.5522	-2.7005	-3.8406	4.0214
SHP-77	GDSC1; GDSC2	-3.5478	-2.7195	-3.8272	3.9225
NCI-H1650	GDSC1; GDSC2	-3.5223	1.1186	-5.7113	15.5141
BEN	GDSC1; GDSC2	-3.5138	5.7524	-8.0199	26.3309
NCI-H345	GDSC1; GDSC2	-3.4729	1.4979	-5.8588	16.212
SK-LU-1	GDSC1; GDSC2	-3.4643	5.4245	-7.8144	25.4285
NCI-H2029	GDSC1; GDSC2	-3.3327	1.2381	-5.611	14.3506
NCI-H2227	GDSC1; GDSC2	-3.3229	1.9025	-5.935	16.1884
NCI-H1105	GDSC2	-3.3054	1.8307	-5.8845	15.8509
NCI-H2135	GDSC1; GDSC2	-3.2496	3.4013	-6.6235	19.6112
NCI-H2818	GDSC1; GDSC2	-3.2372	3.6348	-6.73	20.095
NCI-H322M	GDSC1; GDSC2	-3.1081	0.1942	-4.9051	9.4018
NCI-H727	GDSC1; GDSC2	-3.0991	1.2464	-5.4232	12.5558
HCC827	GDSC1; GDSC2	-3.0978	4.8994	-7.2474	22.0525
RERF-LC-Sq1	GDSC1; GDSC2	-3.0672	0.2449	-4.8978	9.2438
DMS 114	GDSC1; GDSC2	-3.0619	1.4503	-5.495	12.8798
NCI-H146	GDSC2	-3.0249	1.8621	-5.6708	13.8103
NCI-H2023	GDSC1; GDSC2	-2.9833	2.7106	-6.0608	15.8981
NCI-H2795	GDSC1; GDSC2	-2.9589	2.4093	-5.8909	14.8853
NCI-H720	GDSC1; GDSC2	-2.9238	-0.3571	-4.487	6.2952
NCI-H1869	GDSC1; GDSC2	-2.633	1.8673	-5.3672	10.9666
NCI-H1688	GDSC1; GDSC2	-2.53	3.6505	-6.1721	15.261
NCI-H740	GDSC2	-2.3814	5.7744	-7.112	19.4754
NCI-H2196	GDSC1; GDSC2	-2.2021	4.1566	-6.1739	14.4281
SW1573	GDSC1; GDSC2	-1.8316	7.0088	-7.304	18.9204
KNS-62	GDSC2	-1.6006	5.1596	-6.2278	13.2724
NCI-H2373	GDSC1; GDSC2	-1.4085	4.3008	-5.6807	9.9339
NCI-H2803	GDSC1; GDSC2	-1.4054	2.3066	-4.7449	4.7125
NCI-H1341	GDSC2	-1.3553	3.5008	-5.2667	7.5317
NCI-H2731	GDSC1; GDSC2	-1.2831	6.3669	-6.5904	14.3704
PaCa-3	GDSC1; GDSC2	-1.1997	7.4649	-7.0653	16.3928
NCI-H2461	GDSC1; GDSC2	-1.1269	3.3606	-5.0594	5.9662
NCI-H2172	GDSC1; GDSC2	-0.8784	4.5435	-5.4527	7.6608
NCI-H2085	GDSC1; GDSC2	-0.746	6.231	-6.1599	11.1065
NCI-H1993	GDSC1; GDSC2	-0.7219	8.883	-7.4168	16.8634
NCI-H2444	GDSC1; GDSC2	-0.5307	4.0494	-5.0235	4.8232
NCI-H1666	GDSC1; GDSC2	-0.4578	4.8046	-5.3193	6.2377
EKVX	GDSC1; GDSC2	-0.4507	7.1979	-6.4246	11.833
NCI-H196	GDSC1; GDSC2	-0.3912	3.5906	-4.7495	3.2772
NCI-H2066	GDSC2	-0.3393	6.7077	-6.1225	10.141
COR-L95	GDSC1; GDSC2	-0.2909	4.9036	-5.2678	5.7126
NCI-H1573	GDSC1; GDSC2	-0.2818	4.0043	-4.8692	3.7139
DMS 53	GDSC1; GDSC2	-0.1712	4.0618	-4.8364	3.4208
HOP-92	GDSC1; GDSC2	-0.165	7.5005	-6.3829	11.0894
NCI-H2810	GDSC2	-0.0946	5.2862	-5.327	5.7172
DMS 79	GDSC1; GDSC2	-0.0261	4.139	-4.7955	3.0624
NCI-H1693	GDSC1; GDSC2	0.0439	2.755	-4.2169	0.7837
NCI-H1563	GDSC1; GDSC2	0.0705	3.1433	-4.3518	1.1878
NCI-H596	GDSC1; GDSC2	0.1151	7.3885	-6.156	9.4946
NCI-H1435	GDSC1; GDSC2	0.1406	5.7504	-5.401	5.7403
NCI-H2291	GDSC1; GDSC2	0.3393	3.0565	-4.2107	0.6264
LC-1/sq	GDSC1; GDSC2	0.3926	10.5972	-7.4825	14.9101
Lu-165	GDSC1; GDSC2	0.4474	6.4421	-5.5358	5.9577
NCI-H513	GDSC1; GDSC2	0.6274	2.9229	-4.0579	0.2365
NCI-H1838	GDSC1; GDSC2	0.657	2.5828	-3.9341	0.0934

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1; GDSC2	-3.552	1.4111	-5.8828	16.5927

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE-9	GDSC1; GDSC2	-9.6151	-8.553	-9.6152	63.1507
KYSE-510	GDSC1; GDSC2	-8.5421	-7.6851	-8.5421	52.3849
KYSE-150	GDSC1; GDSC2	-7.8783	-5.4732	-7.9118	45.815
T.T	GDSC1; GDSC2	-7.8079	-6.4691	-7.8087	45.0206
KYSE-270	GDSC1; GDSC2	-7.6416	-5.7771	-7.652	43.3898
TE-15	GDSC1; GDSC2	-7.5471	-5.784	-7.5553	42.4351
TE-11	GDSC1; GDSC2	-7.5355	-6.1875	-7.5367	42.2892
TE-10	GDSC1; GDSC2	-7.4812	-4.6663	-7.5772	42.0913
KYSE-180	GDSC1; GDSC2	-7.2444	-5.7306	-7.249	39.3844
TE-4	GDSC2	-7.102	-6.067	-7.1024	37.9354
OE21	GDSC1; GDSC2	-7.057	-2.5708	-7.6255	39.5854
OE19	GDSC1; GDSC2	-6.5995	-5.0468	-6.613	32.9584
KYSE-410	GDSC1; GDSC2	-6.4286	-1.9416	-7.1688	34.5233
TE-5	GDSC1; GDSC2	-5.9205	-1.076	-6.9779	31.2428
KYSE-450	GDSC1; GDSC2	-5.5756	-3.0551	-5.8592	24.1124
KYSE-520	GDSC1; GDSC2	-5.3993	-0.8066	-6.5574	26.9756
TE-8	GDSC1	-4.6199	-0.0498	-6.4925	21.6802
EC-GI-10	GDSC1; GDSC2	-4.4902	-2.1153	-5.0501	14.8895
KYSE-140	GDSC1; GDSC2	-4.3704	0.1079	-5.9735	19.8516
KYSE-70	GDSC1; GDSC2	-4.2877	2.0687	-6.8591	24.1053
OE33	GDSC1; GDSC2	-4.2019	3.0444	-7.2652	25.6073
TE-1	GDSC1; GDSC2	-4.0152	1.7867	-6.4747	21.2934
TE-6	GDSC1; GDSC2	-3.6647	0.8816	-5.7157	15.9857
COLO 680N	GDSC1; GDSC2	-0.9774	11.8806	-9.0687	23.3499

Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TOV-112D	GDSC1; GDSC2	-9.172	-8.134	-9.172	58.7054
OVCAR-4	GDSC1; GDSC2	-8.6809	-6.3865	-8.6932	53.713
Kuramochi	GDSC1; GDSC2	-8.0087	-4.7897	-8.1236	47.2245
OC 314	GDSC1; GDSC2	-7.8564	-7.0028	-7.8564	45.504
IGROV-1	GDSC1; GDSC2	-7.24	-4.506	-7.3425	39.7465
A2780	GDSC1; GDSC2	-7.0566	-3.2911	-7.4062	38.8738
JHOS-4	GDSC2	-6.9367	-2.5218	-7.5111	38.5246
EFO-27	GDSC1; GDSC2	-6.7177	-3.5208	-6.9754	35.2682
OVCAR-8	GDSC1; GDSC2	-6.4319	-5.2064	-6.4361	31.2299
OVCAR-3	GDSC1; GDSC2	-6.3895	-2.195	-7.0332	33.7747
SK-OV-3	GDSC1; GDSC2	-5.8049	-1.4959	-6.6818	29.3754
DOV13	GDSC2	-5.7435	-2.2111	-6.3336	27.3846
OAW28	GDSC1; GDSC2	-5.6762	-2.4031	-6.1899	26.3339
TYK-nu	GDSC1; GDSC2	-5.0105	-0.3501	-6.3744	24.4442
OV-90	GDSC1; GDSC2	-4.8827	-1.8498	-5.5703	19.5066
TOV-21G	GDSC1; GDSC2	-4.5996	0.2656	-6.2667	22.2897
EFO-21	GDSC1; GDSC2	-4.3775	-1.505	-5.2111	15.4169
OVISE	GDSC1; GDSC2	-4.3359	1.6766	-6.7095	23.567
JHOS-2	GDSC2	-4.1868	0.657	-6.0712	19.7426
Caov-3	GDSC1; GDSC2	-3.7104	1.8851	-6.2558	19.149
RMG-I	GDSC1; GDSC2	-3.6899	1.9355	-6.2633	19.123
ES-2	GDSC1; GDSC2	-3.6471	-2.9573	-3.8155	4.2204
OVK18	GDSC2	-3.3316	0.5488	-5.2654	12.2703
OVCAR-5	GDSC1; GDSC2	-2.2161	4.4285	-6.3186	15.2209
FU-OV-1	GDSC1; GDSC2	-2.1454	5.8684	-6.9772	18.2545
Caov-4	GDSC1; GDSC2	-0.9013	3.0635	-4.7944	4.187
OV56	GDSC2	-0.6518	3.3891	-4.8003	3.8634
OVTOKO	GDSC1; GDSC2	-0.5579	9.7137	-7.7046	17.6849
OAW42	GDSC1; GDSC2	-0.0127	2.5915	-4.1793	0.7075
OVKATE	GDSC1; GDSC2	0.3911	2.4143	-3.9683	0.1624

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KP-4	GDSC1; GDSC2	-8.5012	-7.2667	-8.5013	51.9741
KP-1N	GDSC1; GDSC2	-7.0313	-4.5806	-7.1087	37.5782
BxPC-3	GDSC1; GDSC2	-7.007	-3.2907	-7.3521	38.3904
PaTu 8988t	GDSC1; GDSC2	-6.5103	-5.702	-6.5105	31.9965
Panc 03.27	GDSC1; GDSC2	-6.4077	-2.7651	-6.8565	33.1096
Panc 10.05	GDSC1; GDSC2	-6.3933	-5.0114	-6.4028	30.869
KP-2	GDSC1; GDSC2	-6.1034	-3.2788	-6.3694	29.2677
Capan-1	GDSC1; GDSC2	-6.0119	-3.8595	-6.1302	27.5998
CFPAC-1	GDSC1; GDSC2	-5.7857	-3.1765	-6.0518	26.1125
MIA PaCa-2	GDSC1; GDSC2	-5.4775	-2.7215	-5.8619	23.6828
HPAF-II	GDSC1; GDSC2	-5.4289	-1.1809	-6.4233	26.4374
HuP-T4	GDSC1; GDSC2	-5.0678	-0.8583	-6.1981	23.7546
MZ-PC-1	GDSC1; GDSC2	-5.0166	0.3504	-6.7089	26.1235
HPAC	GDSC1; GDSC2	-4.8927	0.5511	-6.6844	25.5182
KP-3	GDSC1; GDSC2	-4.8676	-2.2906	-5.3705	18.2934
PaTu 8902	GDSC1; GDSC2	-4.618	-0.3598	-5.9851	20.8304
Panc 08.13	GDSC1; GDSC2	-4.0628	0.7241	-5.9913	18.871
PSN1	GDSC1; GDSC2	-3.4528	6.2855	-8.2351	26.8993
PL4	GDSC1; GDSC2	-3.0779	2.1392	-5.8519	15.0016
DAN-G	GDSC1; GDSC2	-2.812	2.1013	-5.6212	12.9346
Panc 02.03	GDSC1; GDSC2	-2.3288	4.9424	-6.6584	17.2187
HuP-T3	GDSC1; GDSC2	-2.0398	3.1899	-5.581	10.7678
QGP-1	GDSC2	-1.6647	11.0429	-9.1743	25.2063
Panc 04.03	GDSC1; GDSC2	-1.0899	2.9427	-4.8477	4.7565
Hs 766T	GDSC1; GDSC2	-0.7546	6.1541	-6.1291	10.9677
SUIT-2	GDSC1; GDSC2	-0.06	4.8636	-5.1223	4.653
SU.86.86	GDSC1; GDSC2	-0.0478	5.3556	-5.3315	5.6708
SW1990	GDSC1; GDSC2	-0.0163	5.4835	-5.3705	5.8187
YAPC	GDSC1; GDSC2	0.3919	5.0736	-4.9775	3.4133
AsPC-1	GDSC1; GDSC2	0.4288	3.8969	-4.4876	1.4043
Capan-2	GDSC1; GDSC2	0.8116	4.6798	-4.6244	1.6066

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H2052	GDSC1; GDSC2	-4.0081	-0.0773	-5.5464	16.1145
MPP 89	GDSC1; GDSC2	-0.425	8.709	-7.1279	15.014
NCI-H28	GDSC1; GDSC2	-0.2046	6.7708	-6.0674	9.6228
NCI-H2452	GDSC1; GDSC2	0.0758	9.2128	-7.0342	13.6212
MSTO-211H	GDSC1; GDSC2	0.3477	2.3292	-3.9547	0.1533
IST-Mes1	GDSC1; GDSC2	1.2583	15.7421	-9.3598	19.8761

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DU145	GDSC1; GDSC2	-7.3678	-4.9552	-7.4216	40.8237
22Rv1	GDSC1; GDSC2	-6.5554	-3.5255	-6.7973	33.6106
VCaP	GDSC1; GDSC2	-6.0035	-2.3507	-6.5611	29.7337
LNCaP clone FGC	GDSC1; GDSC2	-5.0835	0.8985	-7.0341	27.8712
PC-3	GDSC1; GDSC2	-3.0526	1.0546	-5.29	11.6208
NCI-H660	GDSC2	-0.1953	2.172	-4.0979	0.5779

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC1; GDSC2	-8.6581	-4.9776	-8.7912	53.2021

Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 829	GDSC1; GDSC2	-10.6139	6.2207	-14.9979	57.2317
HT-144	GDSC1; GDSC2	-10.0148	-6.6384	-10.0537	65.6274
Mel Ho	GDSC1; GDSC2	-9.0054	-7.5721	-9.0056	57.0261
IGR-1	GDSC1; GDSC2	-8.9383	-7.4229	-8.9387	56.35
COLO 679	GDSC1; GDSC2	-8.5344	-6.2606	-8.5478	52.2703
A-431	GDSC1; GDSC2	-8.0734	-6.8462	-8.0736	47.6819
A2058	GDSC1; GDSC2	-8.0005	-6.1977	-8.006	46.9648
CHL-1	GDSC1; GDSC2	-7.8974	-7.0917	-7.8974	45.9149
G-361	GDSC1; GDSC2	-7.762	-6.026	-7.7677	44.5777
Mel JuSo	GDSC1; GDSC2	-7.4525	-4.5401	-7.5651	41.8659
A-388	GDSC1; GDSC2	-7.0137	-2.4393	-7.6223	39.3217
RPMI-7951	GDSC1; GDSC2	-6.8553	-4.0017	-7.0159	36.197
RVH-421	GDSC1; GDSC2	-6.6444	1.2634	-8.7489	40.1272
A101D	GDSC1; GDSC2	-6.6149	-1.0249	-7.7269	37.4397
SK-MEL-2	GDSC1; GDSC2	-6.5326	-3.5974	-6.7546	33.2947
COLO 800	GDSC1; GDSC2	-6.5158	-5.0076	-6.5288	32.1159
HMV-II	GDSC1; GDSC2	-6.3116	-1.3776	-7.264	34.2965
Hs 940.T	GDSC1; GDSC2	-6.1895	-3.8499	-6.3247	29.4628
IGR-37	GDSC1; GDSC2	-6.1162	-4.2533	-6.1768	28.3481
SK-MEL-30	GDSC1; GDSC2	-6.008	-1.696	-6.8152	30.9423
M14	GDSC1; GDSC2	-5.9908	-3.5382	-6.1785	27.7478
DJM-1	GDSC1; GDSC2	-5.9389	-1.6885	-6.7451	30.295
MZ-MEL-7	GDSC1; GDSC2	-5.8695	-0.8936	-7.0026	31.1112
451Lu	GDSC1; GDSC2	-5.864	-0.8378	-7.021	31.164
SK-MEL-3	GDSC1; GDSC2	-5.7423	-2.5574	-6.2056	26.7186
MeWo	GDSC1; GDSC2	-5.7108	-2.3871	-6.233	26.7165
WM35	GDSC1; GDSC2	-5.1226	-0.6992	-6.3256	24.6477
IPC-298	GDSC1; GDSC2	-5.0734	-0.9521	-6.1614	23.5816
Hs 938.T	GDSC1; GDSC2	-4.8624	-1.0093	-5.923	21.4296
WM1552C	GDSC1; GDSC2	-4.844	-2.3186	-5.3343	17.9874
MZ-MEL-2	GDSC1; GDSC2	-4.8379	1.5103	-7.0941	27.1733
WM793	GDSC1; GDSC2	-4.7916	0.3358	-6.4842	24.1422
A-375	GDSC1; GDSC2	-4.7762	-2.3823	-5.2369	17.1436
G-mel	GDSC1; GDSC2	-4.6833	-2.6154	-5.0464	15.6574
WM278	GDSC1; GDSC2	-4.3677	-1.015	-5.4313	16.6982
UACC-62	GDSC1; GDSC2	-4.3668	0.9559	-6.3838	22.0499
CP50-MEL-B	GDSC1; GDSC2	-4.3598	0.17	-5.9936	19.9259
MMAc-SF	GDSC1; GDSC2	-4.2203	0.9362	-6.2393	20.771
SH-4	GDSC1; GDSC2	-4.1699	3.0043	-7.2169	25.2932
LOX-IMVI	GDSC1; GDSC2	-3.9173	4.8998	-7.9389	27.2891
UACC-257	GDSC1; GDSC2	-3.5335	2.4332	-6.3777	19.2308
CP66-MEL	GDSC1; GDSC2	-3.5176	1.4342	-5.8649	16.3844
SK-MEL-5	GDSC1; GDSC2	-3.4494	1.8461	-6.0129	17.0072
SK-MEL-24	GDSC1; GDSC2	-3.3559	-0.5152	-4.7537	9.1585
COLO 783	GDSC1; GDSC2	-3.3302	0.4218	-5.2007	11.8693
COLO 792	GDSC1; GDSC2	-3.2716	0.8083	-5.3452	12.5804
SK-MEL-28	GDSC1; GDSC2	-3.2656	-1.3966	-4.238	5.6383
IST-MEL1	GDSC1; GDSC2	-2.8634	3.4361	-6.3268	16.9848
GAK	GDSC1; GDSC2	-2.7258	5.2052	-7.0995	20.3478
WM115	GDSC1; GDSC2	-2.1827	5.0126	-6.5821	16.4687
LB2518-MEL	GDSC1; GDSC2	-1.7049	9.1111	-8.2477	22.3029
WT2-iPS	GDSC1; GDSC2	-1.2976	3.6584	-5.3038	7.6278
SK-MEL-31	GDSC2	-1.2001	6.1465	-6.4257	13.3812
LB373-MEL-D	GDSC1; GDSC2	-1.1323	6.5901	-6.593	14.0513
SK-MEL-1	GDSC1; GDSC2	-0.8903	2.6927	-4.6262	3.3141
VMRC-MELG	GDSC1; GDSC2	0.4241	9.9246	-7.1441	13.4464
EquiPSC Line K2	GDSC1; GDSC2	-4.0563	0.3463	-5.799	17.7584

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1; GDSC2	-8.5781	-6.7689	-8.5809	52.7328

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-UT-1	GDSC1; GDSC2	-8.7363	-8.0288	-8.7363	54.3339
SK-LMS-1	GDSC1; GDSC2	-8.528	-6.9439	-8.529	52.2386
HT-1080	GDSC1; GDSC2	-8.3347	-7.3713	-8.3348	50.3041
A-204	GDSC1; GDSC2	-7.1751	-3.1219	-7.5833	40.1667
MFH-ino	GDSC1; GDSC2	-7.1203	-3.4361	-7.4366	39.3586
SW982	GDSC1; GDSC2	-7.0226	-4.1287	-7.1723	37.7959
RD	GDSC1; GDSC2	-7.0011	-4.4035	-7.1019	37.3793
SW872	GDSC1; GDSC2	-6.9253	-4.335	-7.0313	36.6507
EW-8	GDSC1; GDSC2	-6.8985	-5.725	-6.8998	35.898
STS-0421	GDSC1; GDSC2	-6.8033	-3.9545	-6.9691	35.7074
VA-ES-BJ	GDSC1; GDSC2	-6.764	-2.5619	-7.3103	36.8541
Rh41	GDSC1; GDSC2	-6.7521	-2.9287	-7.1797	36.2952
KYM-1	GDSC1; GDSC2	-6.6168	-4.0003	-6.7578	33.749
MES-SA	GDSC1; GDSC2	-6.4806	-4.5739	-6.525	31.9196
G-401	GDSC1; GDSC2	-6.3413	-3.5032	-6.5694	31.4351
Hs 633.T	GDSC1; GDSC2	-6.2128	-4.7907	-6.2275	29.0839
RKN	GDSC1; GDSC2	-5.4173	-3.7375	-5.51	21.5062
Rh30	GDSC1; GDSC2	-5.227	-0.7023	-6.4294	25.6105
TE 441.T	GDSC1; GDSC2	-5.137	-1.8166	-5.8489	22.1344
G-402	GDSC1; GDSC2	-4.8515	1.2801	-6.9955	26.7938
GCT	GDSC1; GDSC2	-3.126	6.7662	-8.2037	25.8463
SW684	GDSC1; GDSC2	-0.2045	11.0376	-8.0988	18.4593

Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ECC12	GDSC1; GDSC2	-9.2496	-5.9988	-9.3025	58.8135
MKN28	GDSC1; GDSC2	-8.116	-5.5206	-8.1562	48.1644
HGC-27	GDSC1; GDSC2	-8.0029	-4.6015	-8.1465	47.2081
RF-48	GDSC1; GDSC2	-7.857	-5.4807	-7.8892	45.6011
NUGC-3	GDSC1; GDSC2	-7.7354	-4.2387	-7.9227	44.7763
TMK-1	GDSC1; GDSC2	-7.6593	-6.625	-7.6593	43.5259
IM95	GDSC1; GDSC2	-7.6426	-5.1242	-7.6943	43.5376
23132/87	GDSC1; GDSC2	-7.5616	-6.2164	-7.5628	42.5515
SK-GT-2	GDSC2	-7.461	0.4948	-9.2471	44.9644
AGS	GDSC1; GDSC2	-7.362	-2.6658	-7.9262	42.2585
MKN45	GDSC1; GDSC2	-6.0164	2.1264	-8.5228	36.8101
MKN1	GDSC1; GDSC2	-5.7286	-1.933	-6.425	27.7786
ECC10	GDSC1; GDSC2	-5.6869	0.1609	-7.2843	31.4392
TGBC11TKB	GDSC1; GDSC2	-5.5452	-2.5755	-5.9865	24.6608
RERF-GC-1B	GDSC1; GDSC2	-4.7582	2.6786	-7.5896	28.8794
SNU-5	GDSC1; GDSC2	-4.7228	-2.5291	-5.122	16.2581
NCI-N87	GDSC1; GDSC2	-4.1901	2.3081	-6.8895	23.9069
SNU-16	GDSC1	-3.9239	-1.0739	-5.377	10.9462
OCUM-1	GDSC1; GDSC2	-3.8326	0.978	-5.911	17.6496
HSC-39	GDSC1; GDSC2	-3.8121	-1.5257	-4.6554	9.9838
SNU-1	GDSC1; GDSC2	-3.7819	1.5588	-6.1555	18.8402
GCIY	GDSC1; GDSC2	-3.5097	1.5393	-5.9107	16.62
SCH	GDSC1; GDSC2	-3.4976	0.6249	-5.4436	13.8513
NUGC-4	GDSC1; GDSC2	-3.3005	2.6412	-6.2857	18.0355
MKN7	GDSC1; GDSC2	-3.1897	1.4244	-5.5858	13.7826
Hs 746.T	GDSC1; GDSC2	-2.895	0.4713	-4.8755	8.6456
Fu97	GDSC1; GDSC2	-0.5798	6.3043	-6.0866	10.4133
KATO III	GDSC2	-0.5497	4.0899	-5.0521	4.9979
SNG-M	GDSC1; GDSC2	-8.0975	-6.3858	-8.1009	47.9303

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CGTH-W-1	GDSC1; GDSC2	-8.7216	-4.8974	-8.8714	53.7302
KMH-2	GDSC1; GDSC2	-8.7198	-7.1203	-8.7207	54.1589
ML-1 [Human leukemia]	GDSC1; GDSC2	-8.0211	-5.7656	-8.042	47.2015
IHH-4	GDSC1; GDSC2	-7.9731	-6.7012	-7.9735	46.676
8505C	GDSC1; GDSC2	-7.6655	-5.5307	-7.6874	43.6688
B-CPAP	GDSC1; GDSC2	-7.362	-2.4044	-8.0117	42.4544
CAL-62	GDSC1; GDSC2	-6.7236	-3.9736	-6.8788	34.8724
8305C	GDSC1; GDSC2	-6.2893	-1.7286	-7.1013	33.5449
HTC-C3	GDSC1; GDSC2	-5.3528	-2.3204	-5.8743	23.1982
K5	GDSC1; GDSC2	-4.5651	-0.5348	-5.8507	19.8762
ASH-3	GDSC1; GDSC2	-3.4781	2.7481	-6.488	19.626
BHT-101	GDSC1; GDSC2	-3.4608	-1.6478	-4.2774	6.4656
FTC-133	GDSC1	-0.5902	8.7948	-7.7997	16.3764
WRO	GDSC1; GDSC2	0.0347	7.3114	-6.1698	9.7008
TT	GDSC1; GDSC2	0.0833	1.9656	-3.9237	0.16
TT2609-C02	GDSC1; GDSC2	0.3125	9.2363	-6.8921	12.557

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
BB30-HNC	GDSC1; GDSC2	-9.6829	-7.1812	-9.6914	63.4031
PCI-06A	GDSC1; GDSC2	-9.1001	-7.9701	-9.1002	57.9835
JHU-011	GDSC1; GDSC2	-8.4355	-6.2521	-8.447	51.2978
NCI-H3118	GDSC1; GDSC2	-8.2072	-7.0714	-8.2073	49.0246
JHU-029	GDSC1; GDSC2	-8.1514	-5.7339	-8.1784	48.4974
HSC-2	GDSC1; GDSC2	-7.8475	-5.3449	-7.8895	45.5315
PCI-04B	GDSC1; GDSC2	-7.6983	-5.3456	-7.7336	44.0381
Ca9-22	GDSC1; GDSC2	-7.6772	-6.2835	-7.6786	43.7118
HO-1-N-1	GDSC1; GDSC2	-7.668	-6.0471	-7.672	43.6298
KON	GDSC1; GDSC2	-7.6591	-5.2582	-7.6996	43.6655
KOSC-2	GDSC1; GDSC2	-7.4002	-3.7498	-7.6635	41.8238
OSC-19	GDSC1; GDSC2	-7.2975	-5.7238	-7.303	39.9213
CAL-33	GDSC1; GDSC2	-7.2853	-4.9838	-7.3318	39.9747
HSC-3	GDSC1; GDSC2	-7.2722	-4.0379	-7.4607	40.3712
Detroit 562	GDSC1; GDSC2	-7.1484	-4.2625	-7.2838	38.9736
CAL-27	GDSC1; GDSC2	-6.7791	-4.6103	-6.8368	34.9732
SCC-4	GDSC1; GDSC2	-6.7276	-3.0853	-7.1059	35.8673
BHY	GDSC1; GDSC2	-6.6438	-3.101	-7.0098	35.0151
PCI-38	GDSC1	-6.4384	-4.6661	-6.5103	31.3568
OSC-20	GDSC1; GDSC2	-6.4237	-4.434	-6.4808	31.4127
LB771-HNC	GDSC1; GDSC2	-6.3089	0.5709	-8.0975	36.9999
SCC-9	GDSC1; GDSC2	-6.2839	-1.8145	-7.0623	33.3585
PCI-15A	GDSC1; GDSC2	-6.1742	-1.6584	-7.0065	32.5815
DOK	GDSC1; GDSC2	-5.688	-1.6818	-6.4827	27.8811
BB49-HNC	GDSC1; GDSC2	-5.506	-4.0398	-5.5548	22.1664
BICR 10	GDSC1; GDSC2	-5.316	-1.6368	-6.1113	24.3269
UPCI-SCC-090	GDSC1; GDSC2	-4.9068	1.285	-7.0503	27.2476
FaDu	GDSC1; GDSC2	-4.7445	4.7725	-8.6083	32.1869
SCC-15	GDSC1; GDSC2	-4.5185	0.3491	-6.2301	21.794
BICR 22	GDSC1; GDSC2	-3.9447	-1.0003	-5.0353	12.7932
BICR 78	GDSC1; GDSC2	-3.9282	0.8583	-5.9366	18.1104
SKN-3	GDSC1; GDSC2	-2.7613	4.3102	-6.6814	18.4916
HO-1-u-1	GDSC1; GDSC2	-2.5852	2.8041	-5.7947	13.3294
PE/CA-PJ15	GDSC1; GDSC2	-2.1529	2.6211	-5.3845	9.8978
PCI-30	GDSC1; GDSC2	-1.0188	3.7196	-5.1588	6.3205
SAT [Human HNSCC]	GDSC1; GDSC2	-0.9807	8.1743	-7.2551	16.7383
SAS	GDSC1; GDSC2	-0.159	2.8436	-4.335	1.2913
SCC-25	GDSC1; GDSC2	0.1719	5.5413	-5.2921	5.1636
BICR 31	GDSC1; GDSC2	0.2344	9.7503	-7.1849	13.9711
HSC-4	GDSC1; GDSC2	0.5151	6.8988	-5.6998	6.6477
JHU-022	GDSC1; GDSC2	0.8529	8.37	-6.1643	8.3331

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RT-112	GDSC1; GDSC2	-8.0404	-6.904	-8.0405	47.3509
5637	GDSC1; GDSC2	-8.0362	-6.4579	-8.0382	47.3136
BFTC-905	GDSC1; GDSC2	-7.4528	-5.0656	-7.5003	41.644
SW1710	GDSC1; GDSC2	-7.3846	-3.5406	-7.6979	41.8203
639V	GDSC1; GDSC2	-6.8179	-4.6366	-6.8749	35.358
CAL-29	GDSC1; GDSC2	-5.5372	-0.2786	-6.934	29.3229
SW780	GDSC1; GDSC2	-5.3945	-0.098	-6.8729	28.4374
UM-UC-3	GDSC1; GDSC2	-5.332	-2.2847	-5.8658	23.0607
TCCSUP	GDSC1; GDSC2	-4.9898	1.8482	-7.4012	29.0248
647V	GDSC1; GDSC2	-4.5019	1.9052	-6.9739	25.394
HT-1376	GDSC1; GDSC2	-3.5495	1.1229	-5.7368	15.7465
KU-19-19	GDSC1; GDSC2	-3.5111	2.8235	-6.5537	20.0599
RT-4	GDSC1; GDSC2	-3.3556	7.214	-8.6179	27.8633
T24	GDSC1; GDSC2	-1.1197	5.761	-6.1851	11.9978
HT-1197	GDSC1; GDSC2	-0.6316	11.4591	-8.6079	21.1336
J82	GDSC1; GDSC2	0.2562	8.6244	-6.6416	11.5323

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NT2-D1	GDSC1; GDSC2	-9.6222	-5.4724	-9.7521	61.3429
BPH-1	GDSC1; GDSC2	-9.0823	-6.6529	-9.0943	57.6214
PA-1	GDSC1; GDSC2	-8.0626	-5.2723	-8.1219	47.6676
SW954	GDSC1; GDSC2	-7.6119	-6.3479	-7.6125	43.0529
DoTc2 4510	GDSC1; GDSC2	-7.5731	-4.0569	-7.7833	43.3048
CAL-39	GDSC1; GDSC2	-7.5538	-4.6359	-7.6592	42.8299
MS751	GDSC1; GDSC2	-7.5498	-6.1919	-7.5511	42.4333
NCC-IT	GDSC1; GDSC2	-7.533	-5.9652	-7.5369	42.276
PWR-1E	GDSC2	-7.2888	-4.607	-7.3799	40.1839
SiSo	GDSC1; GDSC2	-7.1578	-5.871	-7.1594	38.5012
TC-YIK	GDSC2	-6.8148	-2.5204	-7.3794	37.3856
C-4-I	GDSC1; GDSC2	-6.6343	-4.7573	-6.669	33.4125
C-33 A	GDSC1; GDSC2	-6.5262	-3.7564	-6.7105	33.0545
KGN	GDSC1; GDSC2	-6.3951	-3.4908	-6.6312	32.005
JEG-3	GDSC1; GDSC2	-6.1023	-3.4037	-6.3343	29.0845
DSH1	GDSC1; GDSC2	-5.9409	1.005	-7.9254	34.8139
Ca Ski	GDSC1; GDSC2	-5.8176	-0.6201	-7.0677	31.1474
ACC-OV7	GDSC2	-5.808	-0.9421	-6.9182	30.4631
NEC8	GDSC1; GDSC2	-5.4223	-1.842	-6.1376	24.9267
HeLa	GDSC1; GDSC2	-5.2103	-3.8363	-5.2685	19.2487
HEC-1	GDSC1; GDSC2	-5.1319	0.1042	-6.7059	26.5738
PEO1	GDSC2	-4.9907	-1.3444	-5.9019	21.8264
HEY	GDSC2	-4.785	0.4234	-6.5198	24.2951
UWB1.289	GDSC2	-4.7575	-0.5896	-6.0129	21.5181
OVMIU	GDSC1; GDSC2	-4.7395	0.7224	-6.62	24.6158
SW962	GDSC1; GDSC2	-4.6704	-1.2503	-5.6204	18.9537
JAR	GDSC1; GDSC2	-4.6533	-2.7263	-4.972	15.1034
ME-180	GDSC1; GDSC2	-4.5986	-1.6533	-5.3652	17.1804
SKN	GDSC1; GDSC2	-4.5469	-0.2548	-5.9665	20.4602
OVCA433	GDSC2	-4.4995	4.5902	-8.2976	30.4156
LB831-BLC	GDSC1; GDSC2	-4.4337	-0.9248	-5.5382	17.5758
OMC-1 [Human cervical carcinoma]	GDSC1; GDSC2	-1.6539	3.7406	-5.5783	9.8884
OV17R	GDSC2	-1.5347	3.1357	-5.2104	7.5648
SiHa	GDSC1; GDSC2	-1.0067	5.4925	-5.9811	10.712
SKG-IIIa	GDSC1; GDSC2	-0.7838	7.6907	-6.8834	14.6667
JHOS-3	GDSC2	-0.4974	5.4256	-5.626	7.8984
HT-3	GDSC1; GDSC2	0.0259	17.9492	-11.3127	27.0346
OVCA420	GDSC2	0.1505	2.8579	-4.2123	0.7171
SW756	GDSC1; GDSC2	0.7158	3.1198	-4.0939	0.2706

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vinorelbine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Vinorelbine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Minor	Increased metabolism of Vinorelbine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
LEE011	DMMX75K	Moderate	Decreased metabolism of Vinorelbine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]

Coadministration of a Drug Treating the Disease Different from Vinorelbine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Vinorelbine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[24]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Vinorelbine due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[24]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[20]
Siltuximab	DMGEATB	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Siltuximab.	Anemia [3A00-3A9Z]	[24]
Dronedarone	DMA8FS5	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[25]
Voriconazole	DMAOL2S	Major	Decreased clearance of Vinorelbine due to the transporter inhibition by Voriconazole.	Aspergillosis [1F20]	[26]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Vinorelbine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[26]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Roflumilast.	Asthma [CA23]	[24]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[27]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Vinorelbine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Vinorelbine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[26]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
ABT-492	DMJFD2I	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[27]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Troleandomycin	DMUZNIG	Major	Decreased clearance of Vinorelbine due to the transporter inhibition by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[26]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Vinorelbine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[26]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[29]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Vinorelbine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[30]
Tucatinib	DMBESUA	Major	Decreased clearance of Vinorelbine due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[26]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Vinorelbine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[27]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Vinorelbine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[32]
PF-04449913	DMSB068	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[24]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Vinorelbine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[20]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Vinorelbine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[33]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Vinorelbine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[34]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Vinorelbine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
Nefazodone	DM4ZS8M	Major	Decreased clearance of Vinorelbine due to the transporter inhibition by Nefazodone.	Depression [6A70-6A7Z]	[26]
Griseofulvin	DMK54YG	Moderate	Increased metabolism of Vinorelbine caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[32]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Vinorelbine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[36]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Vinorelbine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Vinorelbine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[38]
Fosphenytoin	DMOX3LB	Moderate	Accelerated clearance of Vinorelbine due to the transporter induction by Fosphenytoin.	Epilepsy/seizure [8A61-8A6Z]	[39]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Vinorelbine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Vinorelbine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Vinorelbine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[40]
Itraconazole	DMCR1MV	Major	Decreased clearance of Vinorelbine due to the transporter inhibition by Itraconazole.	Fungal infection [1F29-1F2F]	[26]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Vinorelbine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[41]
Ketoconazole	DMPZI3Q	Major	Decreased clearance of Vinorelbine due to the transporter inhibition by Ketoconazole.	Fungal infection [1F29-1F2F]	[26]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Vinorelbine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[26]
Telaprevir	DMMRV29	Major	Decreased metabolism of Vinorelbine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[26]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Vinorelbine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Vinorelbine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Vinorelbine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[42]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Vinorelbine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Vinorelbine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Vinorelbine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Vinorelbine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Saquinavir	DMG814N	Major	Decreased metabolism of Vinorelbine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Vinorelbine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Vinorelbine and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[45]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Vinorelbine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Vinorelbine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Vinorelbine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Ritonavir	DMU764S	Major	Decreased metabolism of Vinorelbine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Vinorelbine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[47]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[48]
Conivaptan	DM1V329	Major	Decreased metabolism of Vinorelbine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[26]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[20]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Vinorelbine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[49]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Vinorelbine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[32]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Vinorelbine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[24]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Denosumab.	Low bone mass disorder [FB83]	[50]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Vinorelbine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[51]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Vinorelbine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[52]
Ceritinib	DMB920Z	Major	Decreased metabolism of Vinorelbine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[26]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Vinorelbine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[53]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Vinorelbine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[24]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[54]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Vinorelbine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
Idelalisib	DM602WT	Major	Decreased metabolism of Vinorelbine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[26]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Vinorelbine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[55]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Vinorelbine caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[56]
LGX818	DMNQXV8	Moderate	Increased metabolism of Vinorelbine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[57]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Vinorelbine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[24]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[58]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Vinorelbine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[59]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Vinorelbine and Thalidomide.	Multiple myeloma [2A83]	[60]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Tecfidera.	Multiple sclerosis [8A40]	[61]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Vinorelbine and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Vinorelbine and Fingolimod.	Multiple sclerosis [8A40]	[62]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Ocrelizumab.	Multiple sclerosis [8A40]	[63]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Vinorelbine and Ozanimod.	Multiple sclerosis [8A40]	[24]
Rifabutin	DM1YBHK	Moderate	Accelerated clearance of Vinorelbine due to the transporter induction by Rifabutin.	Mycobacterium infection [1B10-1B21]	[32]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Vinorelbine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Vinorelbine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[64]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[65]
Modafinil	DMYILBE	Minor	Increased metabolism of Vinorelbine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[21]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Vinorelbine due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[66]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Vinorelbine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[67]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Vinorelbine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[68]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Vinorelbine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[69]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Vinorelbine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[26]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Vinorelbine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[70]
Ustekinumab	DMHTYK3	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Ustekinumab.	Psoriasis [EA90]	[24]
Tildrakizumab	DMLW9HG	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Tildrakizumab.	Psoriasis [EA90]	[24]
Risankizumab	DMM32GT	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Risankizumab.	Psoriasis [EA90]	[24]
Ixekizumab	DMXW92T	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Ixekizumab.	Psoriasis [EA90]	[24]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Vinorelbine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[71]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Vinorelbine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[72]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[27]
Tocilizumab	DM7J6OR	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Tocilizumab.	Rheumatoid arthritis [FA20]	[24]
Canakinumab	DM8HLO5	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Canakinumab.	Rheumatoid arthritis [FA20]	[24]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Rilonacept.	Rheumatoid arthritis [FA20]	[24]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Vinorelbine and Golimumab.	Rheumatoid arthritis [FA20]	[73]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Vinorelbine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[32]
Sarilumab	DMOGNXY	Moderate	Additive immunosuppressive effects by the combination of Vinorelbine and Sarilumab.	Rheumatoid arthritis [FA20]	[24]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Vinorelbine and Leflunomide.	Rheumatoid arthritis [FA20]	[47]
Fentanyl	DM8WAHT	Moderate	Decreased metabolism of Vinorelbine caused by Fentanyl mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[74]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Vinorelbine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[75]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Vinorelbine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[76]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Vinorelbine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[24]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Vinorelbine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[24]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Vinorelbine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[77]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Vinorelbine caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[24]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Vinorelbine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[72]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Azathioprine.	Transplant rejection [NE84]	[20]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Vinorelbine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[72]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[27]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[27]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[27]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Ganciclovir.	Virus infection [1A24-1D9Z]	[20]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Vinorelbine and Valganciclovir.	Virus infection [1A24-1D9Z]	[20]

References

• [1] Vinorelbine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7105).
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Vinorelbine Tartrate
• [6] The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol. 1994 Oct;21(5 Suppl 10):21-7.
• [7] Metabolism pathway of vinorelbine (Navelbine?) in human: Characterisation of the metabolites by HPLCCMS/MS
• [8] Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
• [9] Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.
• [10] Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
• [11] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [12] Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues. Biomed Pharmacother. 2007 Oct;61(9):596-600.
• [13] Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism. Cancer Immunol Immunother. 2003 Jul;52(7):429-37. doi: 10.1007/s00262-003-0386-7. Epub 2003 Apr 15.
• [14] High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Leuk Lymphoma. 2008 Jun;49(6):1202-5. doi: 10.1080/10428190802094237.
• [15] Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
• [16] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [17] Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
• [18] Identification and Profiling of Environmental Chemicals That Inhibit the TGF/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11.
• [19] Acquired protein C deficiency following cisplatinum-navelbine administration for locally advanced breast cancer. Case report. Eur J Gynaecol Oncol. 1999;20(4):323-4.
• [20] Cerner Multum, Inc. "Australian Product Information.".
• [21] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [22] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
• [23] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [24] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [25] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [26] Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
• [27] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [28] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [29] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [30] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [31] Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [32] Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
• [33] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [34] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [35] Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
• [36] Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [38] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [39] Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
• [40] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [41] Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
• [42] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
• [43] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [44] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [45] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
• [46] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [47] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [48] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [49] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [50] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [51] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [52] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [53] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [54] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [55] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [56] Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
• [57] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [58] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [59] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [60] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [61] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [62] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [63] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [64] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [65] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [66] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [67] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [68] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [69] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [70] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [71] Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
• [72] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [73] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [74] Labroo RB, Paine MF, Thummel KE, Kharasch ED "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implicaitons for interindividual variability in disposition, efficacy, and drug interactions." Drug Metab Dispos 25 (1997): 1072-80. [PMID: 9311623]
• [75] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [76] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [77] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.